



# BIO CHINA | 2026 Fusion Forward

International Convention

March 12-14, 2026 Suzhou International Expo Center


Strategic Ecosystem Partner  
战略生态伙伴



Ecosystem Partner  
生态伙伴



Platinum Sponsor  
铂金赞助商



Gold Sponsor  
黄金赞助商



✉ BIOCHINA@enmore.com

# About BIOCHINA

BIOCHINA 2026 (11th) will be held from **March 12-14** at the Suzhou International Expo Center.



Following the success of BIOCHINA 2025 (10th), which welcomed **30,000 attendees** in Suzhou, BIOCHINA continues its journey of boundless innovation and collaborative growth!

Over the past decade, BIOCHINA has **expanded from China's thriving biopharmaceutical sector to the world stage**, establishing an international platform for industry connectivity and uniting global expertise to advance collaboration.

Through **technological breakthroughs, commercial implementation, capital support, and ecosystem integration**, BIOCHINA has witnessed China's innovative drug industry evolve from following to leading, progressing alongside the industry and the times.

## BIOCHINA 2026 Fusion & Forward

'Fusion' embodies the power of an ecosystem, where diverse forces converge to unlock growth. 'Forward' represents future direction, pushing boundaries to define new heights for the industry. Standing at the threshold of a new decade, BIOCHINA 2026 will join hands with global partners to step into the next golden era of China's biopharmaceutical industry.



If you are interested in **Early-stage Research and Clinical Development**, you can click on each module to view more details:

**New Clinical Models** 【BD Post-Deal Clinical – IIT Models – AI in Clinical Trials】

**Indication Development** 【Cardiovascular – Kidney – Oncology – CNS – Metabolism – Ophthalmology – Autoimmune】

**AI in Drug Development** 【Target Discovery – Clinical Translation – R&D Efficiency】

**Small Molecule Drugs** 【Undruggable Targets – Molecular Glues – Oncology – Autoimmune – CNS】

**Antibody Drugs** 【Logic-Gated Technology – NKCE – MCE – PD1/VEGF Bispecifics – TCE – Tri-specifics – Combination Therapy】

**ADC & XDC Drugs** 【Dual-Payload ADC – Bispecific ADC – DAC – Bi-XDC – PDC – Computational Pathology – Autoimmune – Combination Therapy】

**Radiopharmaceuticals** 【Radionuclide Selection – Ligand Selection – Early Development – Clinical Indications】

**Cell Therapy** 【Synthetic NK Anti-Aging – Immunotherapy – CAR-T Solid Tumors – TCR-T Solid Tumors – CAR-NK Solid Tumors】

**In-vivo CART** 【LVV – LNP – Regulatory – Oncology – In vivo CAR-T – In vivo TCR-T – In vivo CAR Macrophage】

**Stem Cell Therapies** 【iPSC – MSC – Parkinson's Disease – Heart Failure – Ischemic Vascular Disease – Knee Osteoarthritis – Type 2 Diabetes – Acute Ischemic Stroke – Liver Cirrhosis – Liver Failure】

**Regenerative Medicine** 【Progenitor Cells – iPSC Regenerative Transplantation – Organoids – Tissue Engineering – Tissue Repair】

**Gene Therapy** 【Parkinson's Disease – Heart Failure – Oncology – Ophthalmology – Rare Diseases – Chronic Diseases】

**Oligonucleotide Drugs** 【Cardiovascular – Metabolism – Oncology – Hepatitis B – Lipid Reduction – Non-Hepatic Targets】

**mRNA Drugs** 【Cancer Vaccines – Fat-Targeting – Circular RNA – Base Editing】

**Peptide Drugs** 【Cyclic Peptides – Tri-Target – GLP-1 – Phase III Clinical Trials】

**Exosome-Based Therapies** 【Extracellular Vesicles – Engineered Exosomes – Delivery】

**Biomanufacturing** 【Cosmetic Ingredients – Novel Food Ingredients – Probiotics – Food & Medicine Homologs – Straw-Based – Microalgae Exosomes】

If you are interested in **process development and manufacturing quality**, you can click on each module to view more details:

**CMC Global Expansion** 【Regulations & Submissions in China, US, and EU – Pharmaceutical Registration & Variations – Technology Transfer & Compliant Manufacturing】

**On-Site Inspections** 【FDA/EMA/PICS Inspections – UAE Inspections – Colombia Audits – Data Integrity】

**Global Regulatory** 【Indonesia – Pakistan】

If you are interested in **process development and manufacturing quality**, you can click on each module to view more details:

**Cell Line Development & Engineering** 【High-Expression Cell Lines – Rapid Cell Line Development – CHO – Bioreactors】

**Upstream & Downstream Process Development & Validation** 【Digital & AI Technologies – Upstream Process – Robust Downstream Scale-Up – 10,000L Purification – Downstream Hierarchy – Downstream Process AI PSO Algorithms】

**Formulation Development** 【ADC Lyophilized Formulations – High-Concentration Antibody Formulations – Inhalation Formulations – Dual-Chamber Lyophilized Formulations – Long-Acting Peptide Formulations – Solid Dispersion Formulations – Aseptic Manufacturing】

**Analytical Testing & Quality Management** 【Updated Pharmacopeia – R&D Quality Management – Process Residue Control – Complex Molecule Quality Analysis – Characterization Analysis】

**Peptide Synthesis** 【Compound Formulations – Process Optimization – Production Optimization – Process Scale-Up】

**Cell Therapy** 【Future Manufacturing – Bedside Preparation – Fast CAR-T】

**In vivo CART** 【Vector Selection – Process Development – CMC】

**AI in Process & Manufacturing** 【Peptides – Nucleic Acid Drugs – Bispecific Antibodies – Fermentation】

**Biomanufacturing** 【New Fermentation Platforms – 10,000-Ton Industrial Fermentation – Enzyme & Metabolic Engineering – Cell Factories – Industrial Strains】

If you are interested in **BD deals and global markets**, you can click on each module to view more details:

**BD Strategy** 【MNC Asia-Pacific Strategy – Pharmaceutical Globalization – NewCo Evolution – Going Global – Payment Solutions】

**Global Investment** 【Investment & Financing Trends – LP-GP Ecosystem – Big Pharma Incubators – Industrial Investments – Hong Kong IPOs – China-US Taxation】

**Finance, Tax & IP** 【Financial & Tax Planning in Deals – Valuation – Global IP Strategy – Due Diligence – Risk Allocation】

**International Markets** 【Australia – Korea – India – Asia – Belt & Road – Russia – Middle East – Latin America】

**Technology & Research Translation** 【University Technology Transfer Models – Professor-Led Startups】

If you are interested in **procurement and supply chain**, you can click on each module to view more details:

**Global Supply Chain** 【Overseas Supply Chain – Europe & US Supply Chain – CGT Supply Chain – Large Molecule Supply Chain – CXO Supply Chain – Reagents & Consumables Procurement – Full-Category Supplier Management – Localization of Key Materials in Import Transfer Projects】

# About the Exhibition

BIOCHINA 2026 (11th Edition) will feature six exhibition halls—**Laboratory Instruments, Pharma Equipment, Raw Materials & Reagents, Consumables, International Services**, and **General Services**. Onsite, participants can connect directly with domestic and international brands, engage with founders and senior technology executives, and enhance business cooperation efficiency between exhibitors, end users, and distribution partners.



 **BIO CHINA** | 2026 **Fusion Forward**  
International Convention

**融合·领先 第十一届易贸生物产业展览**

2026/03/12-14 SUZHOU·CHINA 中国·苏州

**C3 International Service**  
C3 国际服务馆



**D3 Pharma Equipment& Laboratory Instruments**  
制药装备馆 & 实验室仪器馆



**E3 Raw Materials& Reagents&Consumables**  
原料试剂 & 耗材馆



**F3 General Services**  
综合馆



This image is not the final version of the booth layout.  
All rights of final interpretation belong to Enmore.  
此图非最终版展位图，最终解释权归易贸医疗所有

## About the Conference

As a flagship event in China's biopharmaceutical industry, BIOCHINA is dedicated to promoting innovation and industrial translation in the sector. Centered on innovative drugs, the conference provides a comprehensive industry platform connecting research achievements, clinical needs, industrial application, and business development, fostering the exchange of cutting-edge technologies and best practices in industrialization.

In BIOCHINA 2025, the conference invited 74 chairs, Expert Committee Members, and Conference Producers and 850 speakers, creating 204 forums, 12 closed-door meetings, 25 brainstorming sessions, and initiating 10,000+ one-on-one BiOPartnering meetings.

BIOCHINA 2026 will continue to enhance both content and organization, launching 20 inaugural forums. With industry tracks as the core focus, the conference will delve into specialized technologies, promote upstream and downstream industry collaboration, and bring together global experiences, driving efficient development of innovative drugs worldwide.



BiOPartnering offers **1-on-1, 30-minute meetings** to discuss cutting-edge technologies, innovative applications, and industry trends. Tailored to company needs, it facilitates investment, project deals, and strategic collaborations, promoting internationalization of the biotech industry and fostering global cooperation and win-win innovation.

## BiOPartnering Partner



### Partnering Room

1 Large Partnering Room




2 Large Partnering Room



3 Medium Partnering Room



4 Small Partnering Room



## About Overseas

BIOCHINA 2026 is expected to attract participants from **40+ countries and regions**, including key markets such as South Korea, Russia, the United States, and Singapore. Companies from **Asia, Europe, the Americas, and Oceania** will actively engage in collaborations with the Chinese market. A wide range of participation formats will be offered, including international forums, **the International Hall, 1-on-1 BiOPartnering meetings, and networking receptions**, providing a comprehensive platform for companies to explore new business opportunities.

 ENMORE BIO

 BIO CHINA | 2026 Fusion Forward  
International Convention  
March 12-14, 2026 Suzhou International Expo Center

Dr Reddy Inceptua Group Pfizer Inc. Canada India  
Certest Pharma AbTis, Co., Ltd. Daewon Pharm. Co., Ltd.  
Binnopharm Group Celltrion, Inc. Belgium Laboratorios Bago S.A.  
USA Lilly Russia Torrent Pharma PROMAMED Germany  
Spain 100+ senior executives from France  
Novartis global pharmaceutical companies Sweden

Sun Pharma Find Projects Find Partnerships GeroPharma  
GL PharmTech Daewoong Pharmaceutical Insud Pharma  
Thailand Pakistan Singapore Bayer  
United Kingdom Australia  
Argentina Poland Korea  
Pharmasyntez SENJU PHARMACEUTICAL






The First BIOFestival will take place from March 12–14 at the Suzhou International Expo Center, alongside BIOCHINA.

Under the theme “Life’s Light Shining with You,” the festival celebrates the people who bring biotechnology to life. Biotechnology is not just about laboratory data or manufacturing processes—it is about real lives, real health, and a shared future. It safeguards my health, my work, and my tomorrow.

The First BIOFestival focuses not only on breakthrough innovation, but also on the everyday dedication of scientists, engineers, and industry professionals. Each effort is a small light; together, they form a constellation that illuminates the future of human health. Key

Programs & Experiences include Talks on Life Sciences, Engaging Youth with Scientists, a Bacterial Culture Competition, Product Challenges & Playful Experiences, the Future of Life Networking Reception, and an IP Runway Show, offering a dynamic mix of science, creativity, and human connection. Experience Zones include the Charity Art Gallery, Tree of Life – Share Your Wishes, Your Year in Moments – Annual Visual Showcase, and the Share & Shine Interactive Space, creating an emotional bridge between science, life, and the people behind innovation. Where science meets emotion—and every light matters.



BioChina 2026 (11th Edition) Agenda										
Mar12	Time	Room B3	Room C303	Hall C3 Roadshow	Room D304	Room D307	Room C302	Room C301	Room D305	Room D306
		Main Forum		Roadshow	International Forum	/	/	Radiopharmaceutical Innovation Forum	Global Supply Chain Innovation Forum	Innovative Process Technology Forum
	09:00-10:00	BioChina2026 Opening Ceremony		Innovative Drugs	Australia Market	/	/	Future Exploration	/	Quality Analysis
	10:00-11:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
	11:00-12:00		BioBD Forum	Roadshow	Global Forum	Global Regulatory Forum	Global Core Therapeutic Areas Ecosystem Forum	Radiopharmaceutical Innovation Forum	Global Supply Chain Innovation Forum	Innovative Process Technology Forum
	12:00-13:00	Main Forum Interview	BD Strategy	Innovative Drugs	Korea Market	Regulatory Affairs – US & EU Markets	Cardiovascular & Renal Diseases	Innovative R&D	Global Supply Chain Development	Quality Analysis
	13:00-14:00									
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BioBD Forum	Roadshow	Global Forum	Global Regulatory Forum	Global Core Therapeutic Areas Ecosystem Forum	Radiopharmaceutical Innovation Forum	Global Supply Chain Innovation Forum	Innovative Process Technology Forum
	15:00-16:00									
Mar13	16:00-17:00		New Market Landscape	Innovative Technologies / Therapies	Korea Market Asia Market	Regulatory Affairs – APAC & Emerging Markets	Oncology	Clinical Development Future Manufacturing	Local Supply Chain Development	Cell Line Development & Construction
	17:00-18:00									
		Main Forum	BioFUNDING Forum	Roadshow	Global Forum	Global Clinical Development Forum	Global Core Therapeutic Areas Ecosystem Forum	Immunology Innovation Forum	CMC Global Expansion Forum	Innovative Process Technology Forum
	09:00-10:00	MNC Strategy Release	Global BIO Investment	In Vivo CAR-T	Asia Market	Post-Deal BD Clinical Strategy	Neurological Disorders	Immunology Innovation	US & EU Markets	Purification Forum
	10:00-11:00									
	11:00-12:00		Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
			BioFUNDING Forum	Roadshow	Global Forum	Global Clinical Development Forum	Global Core Therapeutic Areas Ecosystem Forum	Immunology Innovation Forum	CMC Global Expansion Forum	Innovative Process Technology Forum
	12:00-13:00									
	13:00-14:00	Strategic Release	Ecosystem & Innovation	Korea Session	Emerging Markets & Belt and Road Regions	Innovative Therapies: New Clinical Models	Metabolic Diseases	Autoimmune Diseases	CMC Global Expansion	Purification Forum Antibody CMC Development & Management
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking
Mar14			BioFUNDING Forum	Roadshow	Global Forum	Global Clinical Development Forum	Global Core Therapeutic Areas Ecosystem Forum	Immunology Innovation Forum	CMC Global Expansion Forum	Innovative Process Technology Forum
	15:00-16:00									
	16:00-17:00		M&A & IPO & Early-Stage Investment	Upstream Session	Russia Market	AI-Enabled Clinical Development	Ophthalmic Diseases	Treg & Nobel Prize Forum	CMC Global Expansion Forum Global Submissions & Regulatory Affairs	Upstream & Downstream Process Development
	17:00-18:00									
			Tax & Finance Law Forum	Roadshow	Global Forum	Innovative Formulation Development Forum	Scientific Achievement Translation Forum	Immunology Innovation Forum	Global Technology Transfer & Compliant Manufacturing Forum	Innovative Process Technology Forum
	09:00-10:00									
	10:00-11:00		Tax & Finance Strategies for Biopharma Companies	AI & Scientific Research	Middle East Markets LATAM Market	Antibody Drug Formulations & Inhalation Formulations: Regulatory and Process Considerations	Translational Practice of Biopharmaceutical Scientific Achievements	Frontier Research	Technology Transfer & Collaborative Manufacturing	ADC Process Development
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking		Networking	Networking
			Global IP Forum	Roadshow	Formulation Innovation Forum	Innovative Formulation Development Forum	Scientific Achievement Translation Forum		Global Technology Transfer & Compliant Manufacturing Forum	Innovative Process Technology Forum
	12:00-13:00									
	13:00-14:00		Global IP Strategy	Biomanufacturing		Novel Biologics: Formulation Manufacturing & Aseptic Processing	Sharing Practical Entrepreneurship Experiences by Professors		Submissions & Inspections	Analytical Testing Cleanroom & Engineering Equipment

BIOCHINA 2026 (11th Edition) Agenda													
Mar12	Time	Room F312	Room E309	Room E308	Room E311	Room E310	Room F313	Room F314	D3 Brainstorm 1	D3 Brainstorm 2	Main Stage 1	Main Stage 2	
		Small Molecule Drug Innovation Forum		AI Innovation Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Exosome Innovative Development Forum	Biomanufacturing Innovative Development Forum	/	/			
	09:00-10:00	/	Opening Panel Discussion	/	/	/	/	/	/	/	BIOCHINA Awards: Annual Supplier Ceremony	/	
	10:00-11:00	Opening Panel Discussion	Opening Panel Discussion	Opening Panel Discussion	Opening Panel Discussion	Opening Panel Discussion	Opening Panel Discussion	Opening Panel Discussion	/	/			
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	BIOCHINA International Dialogue	BIOCHINA Bio Festival Runway Show	
		Small Molecule Drug Innovation Forum	Oligonucleotide Drug Innovative Development Forum	AI Innovation Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Exosome Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2	
	12:00-13:00	Innovative Drug Development & Global Expansion	Case Sharing Indication	New Drug R&D	Complex Molecule Innovation & Development	Clinical Development	Technological Innovation & Clinical Translation	Food Development	Peptides	In Vivo CAR-T	/	/	
	13:00-14:00												
	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	BIOCHINA Bio Festival	BIOCHINA International Supply & Procurement Dialogue	
		Small Molecule Drug Innovation Forum	Oligonucleotide Drug Innovative Development Forum	AI Innovation Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Exosome Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2	
Mar13	15:00-16:00												
	16:00-17:00	Undruggable Targets Molecular Glues	Technology Development & CMC Strategies	New Drug R&D	Bispecific & Multispecific Antibody Innovation & Development	Innovative R&D	Delivery, Clinical Translation Process Development	Food Development	Antibody CMC	Immune Cell, Cold Chain Logistics & Cell Therapy Quality Control	/	/	
	17:00-18:00												
		Small Molecule Drug Innovation Forum	Peptide Drug Innovative Development Forum	xDCD Drug Innovative Development Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Cell Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2	
	09:00-10:00												
	10:00-11:00	Oncology Drugs	Oral Cyclic Peptides Case Sharing	Global Development & Collaboration	Bispecific & Multispecific Antibody Innovation & Development	Drug Delivery	Future of Manufacturing	Agricultural Innovation	Drug Delivery	Radiopharmaceuticals	/	/	
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	BIOCHINA CEO Dialogue	BIOCHINA Bio Festival Awards	
		Small Molecule Drug Innovation Forum	Peptide Drug Innovative Development Forum	xDCD Drug Innovative Development Forum	Antibody Drug Innovative Development Forum	In Vivo CAR-T Innovation Forum	Cell Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2	
	12:00-13:00												
	13:00-14:00	Multi-Indication	Case Sharing	Latest R&D & Clinical Progress	Bispecific & Multispecific Antibody Innovation & Development	Process & Clinical Research	Autoimmune & Other Disease Drug Development	Pharmaceutical Synthesis	Conjugated Drugs	Artificial Intelligence	/	/	
Mar14	14:00-15:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	BIOCHINA Upstream Dialogue	BIOCHINA CSO Dialogue	
		Small Molecule Drug Innovation Forum	Peptide Drug Innovative Development Forum	xDCD Drug Innovative Development Forum	Antibody Drug Innovative Development Forum	Stem Cell Drug Innovative Development Forum	Cell Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2	
	15:00-16:00												
	16:00-17:00	Clinical Indication Development -CNS	Process & Manufacturing	Differentiated Targets & Molecular Design	Antibody Combination Therapy: From Early Research to CMC Management	Industry Policy & Translation	Solid Tumor Drug Development	Bioaesthetics	Conjugated Drugs	Organoids	/	/	
	17:00-18:00	CMC & Quality		Cutting-Edge Technology Development & Application	ADC Pathology Research								
		AI for Science Forum	Nucleic Acid Drug Innovative Development Forum	xDCD Drug Innovative Development Forum	Regenerative Medicine & Tissue Repair Forum	Stem Cell Drug Innovative Development Forum	Gene Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2	
	09:00-10:00	Basic Research and Core Technology Integration	mRNA Cancer Vaccines	Novel Molecule Design & Development	Regenerative Medicine Empowering Tissue Repair	iPSC	Technological & Clinical Innovation	AI & Biomanufacturing	Cell Therapy CMC & Regulatory	Antibody R&D & Autoimmune Diseases	/	/	
	10:00-11:00												
	11:00-12:00	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	Networking	BIOCHINA CMO Dialogue	BIOCHINA CTO Dialogue	
		AI for Science Forum	Nucleic Acid Drug Innovative Development Forum	xDCD Drug Innovative Development Forum	Regenerative Medicine & Tissue Repair Forum	Stem Cell Drug Innovative Development Forum	Gene Therapy Innovative Development Forum	Biomanufacturing Innovative Development Forum	Brainstorm	Brainstorm	Main Stage 1	Main Stage 2	
Mar15	12:00-13:00												
	13:00-14:00	Drug Discovery and Clinical Translation Session	mRNA Potential Development	Innovative Development & New Technologies	Organoids & Tissue Engineering	Regenerative Medicine Empowering Tissue Repair	MSC	Indication Development	AI & Biomanufacturing Accelerating Life Science Research	Cell Therapy Quality	Small Molecule Innovation & Development		
		Clinical Translation Session	Technology Innovation	Delivery & Future Applications				CMC & Regulatory Submission		Stem Cells			

## BIOCHINA2026 Main Forum

Date	March 12th	March 13th
	<p>09:00-09:20   BIOCHINA Opening Ceremony  <b>Guest of Honor:</b> Deepa Talpade, Bayer Pharmaceuticals, SVP and Head BD&amp;L and AllianceManagement, Oncology and Radiology  Dr. Lianshan Zhang, Jiangsu Hengrui Pharmaceuticals, Board Member &amp; Vice President</p> <p>09:20-09:40   BIOCHINA Opening Speech  <b>Speakers:</b> Frank Jiang, M.D., Ph.D., Jiangsu Hengrui Pharmaceuticals, EVP, Chief Strategy Officer, Board Director  Huji Xu, Changzheng Hospital, Professor  Friedemann Janus, Ph.D., Bayer Pharmaceuticals, SVP and Global Head of Bayer Co.Lab, Regional BD&amp;L and Divestitures</p>	<p>09:00-11:00   MNC Strategy Release  <b>Speaker:</b> Albert Ren, Pfizer, Vice President Worldwide Business Development China</p>
09:00-14:00	<p>9:40-10:40   Panel Discussion: Power of Innovation – A Global Perspective on Disruptive Technologies  <b>Moderator:</b> Dr. YongJun Liu, Xiaolu Biomedicine Co., Ltd, Founder  <b>Panelists:</b> Michel GILLIET, CHUV Lausanne University Hospital, Chairman Jenny Ting, The University of North Carolina at Chapel Hill, Professor, Co-Founder of IMMvention Therapeutics</p> <p>10:40-11:10   Presentation: New Strategies and Emerging Trends in Immunotherapy  <b>Speaker:</b> Zhigang Tian, Chinese Academy of Engineering, Academician</p> <p>11:10-11:30   BIOCHINA Awards Ceremony</p>	<p>11:00-12:00   Panel Discussion: Building a Global Partnership Ecosystem Together  <b>Moderator:</b> Weimin Liu, BeOne Medicines Ltd., MD, Life Science VC  <b>Panelists:</b> Ryan Wang, Eli Lilly, Vice President, Lilly China Innovation and Partnerships. Faisal Darwazeh, Hikma Pharmaceuticals, Vice President Group Business Development &amp; Alliances</p> <p>Zhongyuan Zhu, Duality Biotherapeutics, Inc., Founder, Chairman &amp; CEO  Betty Huang, Bayer Pharmaceuticals, VP and Head of Collaborate to Cure Hub China</p>
	<p>11:30-12:30   Panel Discussion: How Can Chinese Pharmaceutical Companies Embrace Globalization?  <b>Moderator:</b> Jiang Zhang, LongRiver Investments, Founder &amp; CEO  <b>Panelists:</b> Aimin Hui, PhD, EnCureGen Pharma, Chair and CEO Yan Liu, Takeda Pharmaceuticals, President, China  Zhisheng Chen, WuXi Biologics (Cayman) Inc., CEO &amp; Chairman, WuXi / WuXi Healthcare Alliance</p> <p>12:30-13:00   Panel Discussion: How is AI Transforming the Biopharmaceutical Industry?  <b>Panelists:</b> Feng Ren, InSilico Intelligence, Co-CEO Runping Guo, Microsoft China, General Manager, Azure Intelligent Cloud Solutions</p>	<p>12:00-13:00   MNC Strategy Release  <b>Speakers:</b> Faisal Darwazeh, Hikma Pharmaceuticals, Vice President Group Business Development &amp; Alliances  Atul Raut, Sun Pharma, Vice President  Dr.Satheeshkumar Sriharan, Dr.Reddy's Laboratories, Group Country Head</p> <p>13:00-14:00   Strategy Release  Cytiva Sitofan Strategic Release: Driving Bioprocess Innovation  <b>Speaker:</b> Cytiva</p>
Concurrent Events	<p>March 12, 18:00-20:00 BIONIGHT 2026 (Exclusive Invitation Dinner)</p> <p>March 12-14 BiOPARTNERING 1V1 Targeted Meetings</p> <p>March 12-14 BIOCHINA 2026 Exhibition</p>	
	<p><b>Back to Contents</b></p>	

BIOCHINA2026 BioBD Forum		BIOCHINA2026 BiOFUNDING Forum	BIOCHINA 2026 Tax & Finance Law Forum
Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	<p><b>BIOFUNDING Forum</b>            09:00-09:20   Presentation: Global Trends in Biopharma Investment and Financing            09:20-10:10   TOP Fund Discussion: BIO Investment Keywords for 2026  <b>Panelists:</b> Marc Appel, Pacific Bridge NY, Managing Partner            Jerry Wu, LongRiver Investments, Managing Director            10:10-11:00   Dual-Currency Healthcare Funds: How to Invest Overseas?  <b>Moderator:</b> Xiaohang Tong, Decheng Capital, Partner  <b>Panelists:</b> Jieyu Zou, Lily Asia Ventures, Managing Director            Henry He, HighLight Capital, CIO, Partner            Lixin Xu, Mingxin Capital, Managing Partner            Dr. Dan LIU, Pivotal BioVenture Partners, Managing Partner</p>	<p><b>Fiscal and Tax Strategies for Chinese Innovative Drug Companies from a BD Perspective</b>            09:00-09:20   Presentation: Tax Planning in Overseas BD Transactions and M&amp;A Exits of Chinese Pharmaceutical Companies  <b>Speaker:</b> Chen Wang, Deloitte, Head of International Tax &amp; M&amp;A Tax, East China, Senior Partner            09:20-09:40   Presentation: The Story Behind the Valuation of Chinese Innovative Drug Companies  <b>Speaker:</b> Xuan Wang, Deloitte China, Partner, M&amp;A Financial Advisory            09:40-10:00   Presentation: Legal Hot Topics in BD Transactions of Chinese Pharmaceutical Companies  <b>Speaker:</b> Hao Zhao, JUN HE LAW OFFICES, Partner            10:00-11:00   Panel Discussion: International Tax Planning for Biopharma IP License-Out and NewCo Transactions  <b>Moderator:</b> Yimin Zhao, Deloitte China, Tax Lead Partner, Life Sciences  <b>Panelists:</b> Shu Zhang, Deloitte China, International Tax Partner, Life Sciences            Jingna Chen, Deloitte China, China Tax Partner, Life Sciences            Yiming Liu, Cooley, Managing Partner, Shanghai</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>BD Strategy</b>            12:00-12:30   Presentation: Insights into BD Deals for Innovative Drugs in China and Global Enablement  <b>Speaker:</b> Jean-Baptiste Duval, the CFI Group, Director Healthcare &amp; Life Sciences            12:30-13:15   MNC Asia-Pacific Strategy  <b>Moderator:</b> Jean-Baptiste Duval, the CFI Group, Director Healthcare &amp; Life Sciences  <b>Panelist:</b> Feng Bian, BMS, Executive Director            Jenny Yang, Novo Nordisk A/S, Head of External Innovation Asia Pacific            13:15-14:00   Global Strategies Of Chinese Big Pharma &amp; Biotech  <b>Moderator:</b> Mingde.xia, Innolake Biopharm, CEO  <b>Panelists:</b> Vivian Feng, Fosun Pharma, General Manager of BD            Mingjiu Chen, PhD, Biosion Inc., Founder, President &amp; CEO            Tony Xue, MediLink Therapeutics, Co-Founder and CEO</p>	<p>12:00-13:00   LP-GP-Biotech Ecosystem: Aligning Policy, Capital, and Innovation  <b>Moderator:</b> Yang Yu, Deloitte China, CGO, Audit &amp; Assurance  <b>Panelists:</b> Xi Yang, Guangzhou Guoju Venture Capital Co., Ltd., Chairman of the Board            Chong Zhang, Green Pine Capital., Partner of the Healthcare Fund            Pai Zhu, EFUNG CAPITAL, CEO            Fei Qi, Ph.D., LEGEND CAPITAL, Executive Director            13:00-14:00   Big Pharma Innovation Radar: Scanning, Investing in, and Incubating the Future  <b>Moderator:</b> Han Dai, Viva BiInnovator, CIO &amp; Head of Investment  <b>Panelists:</b> Di Xu, Bayer Co.Lab, China Head            Congyang Wu, AbbVie Ventures, Head of Strategy &amp; Operations            Liheng Ma, Pfizer, Head of DC Strategy &amp; CGRP Therapeutics            Zhaoying Xu, Ph.D., Lilly Ventures, China, Executive Director            Dr. Jonathan Liu, BeOne Innovation Center / BeOne Biologics / BeOne China BioVentures, CEO / Chairman &amp; GM / Managing Director</p>	<p><b>Global IP Strategies of Chinese Innovative Drug Companies from a BD Perspective</b>            12:00-12:20   Presentation: Value Realization: IP Due Diligence, Valuation, and Risk Allocation in Global BD Transactions  <b>Speaker:</b> Wengqian Wu, Deloitte, Financial Advisory Partner            12:20-12:40   Presentation: Strategy First: A BD-Driven Blueprint for Global IP Deployment  <b>Speaker:</b> Yang Gu, HAN KUN LAW OFFICES, Partner            12:40-13:00   Presentation: Offense and Defense: Building a Practical IP Framework to Support BD Transactions and Market Access  <b>Speaker:</b> Adrian Murray, Brand Murray Fuller LLP, Partner            13:00-14:00   Panel Discussion: Bridging the Gap: Seamless Alignment of IP, BD, and Commercialization  <b>Moderator:</b> Yang Gu, HAN KUN LAW OFFICES, Partner</p>
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	<p>15:00-15:15   Presentation: Topic TBC  <b>Speaker:</b> Tony Cheng, Ph.D, Custom solutions, Norstella China            15:15-16:15   The Evolution and Beyond of NewCo: Multi-Dimensional Collaboration Between MNCs and Chinese Innovative Pharma Companies  <b>Moderator:</b> Jielun Zhu, Excalipoint Therapeutics, Co-Founder, CFO &amp; CBO  <b>Panelists:</b> Dato Liu, Maiwei Biotech, Chairman &amp; General Manager            Chenbing Wu, EpimAb Biotherapeutics Inc, CEO            Friedemann Janus, Ph.D., Bayer Pharmaceuticals, SVP and Global Head of Bayer Co.Lab, Regional BD&amp;L and Divestitures  <b>Market New Landscape</b>            16:15-17:00   Breaking Boundaries in China: Pathways and Practices for Globalizing Innovative Products (In China, for Global)  <b>Moderator:</b> Dr.Satheeshkumar Sriharan, Dr. Reddy's Laboratories, Group Country Head  <b>Panelist:</b> Hua Jiang, Boan Biotech, Chairlady and CEO            Dr. Lianshan Zhang, Jiangsu Hengrui Pharmaceuticals, Board Member &amp; Vice President            Hao Jiang, CSPC Pharmaceutical, General Manager, Business Development            Wei Huang, Henlius Biotech, President            17:00-18:00   Breaking Through Innovative Drug Reimbursement  <b>Planner:</b> Jiang Zhang, LongRiver Investments, Founder &amp; CEO  <b>Panelists:</b> Feiqing Chu, AIA, Head of Health Management Division            Chao Guo, Pacific Life Insurance, Deputy General Manager            Lin Zhang, Pulan Technology, Founder &amp; CEO</p>	<p>15:00-16:00   New Landscape of Industrial Investment: Alliances and Strategic M&amp;A  <b>Moderator:</b> Yueyue Wang, Tianchao Capital, Partner  <b>Panelists:</b> Peng Lin, China Resources Biopharmaceutical Company, Deputy General Manager            Tse Hsin, Sino Biopharmaceutical Limited, Executive Director            Zhisheng Chen, CEO of WuXi Biologics &amp; Chairman of WuXi Head &amp; WuXi AppTec Holdings            16:00-17:00   Panel Discussion: Investor Dialogue – TGIF  <b>Moderator:</b> Jia Li, Lang Sheng Investment Group, Partner  <b>Panelists:</b> Jielun Zhu, Excalipoint Therapeutics, Co-Founder, CFO &amp; CBO            Xinle Niu, Huajin Capital, CIO, Healthcare            Jayson Lee, LongRiver Investments, Partner            17:00-17:30   Presentation: Key Financial Issues in Hong Kong IPOs of Biopharma Companies  <b>Speaker:</b> Lanying Mu, Deloitte, Managing Partner, Audit, China Life Sciences            17:30-18:00   Presentation: US Tax Planning for Founder and Management Equity Incentive Programs Before and After Biopharma IPOs  <b>Speaker:</b> Xuejia Shao, Deloitte, Partner, U.S. Tax, Private Equity &amp; Life Sciences</p>	<p><b>Back to Contents</b> <span style="float: right;">13</span></p>

Date	March 12th	March 13th	March 14th
09:00-11:00	<p>09:00-10:00   Exhibition Hall Closed During Opening Ceremony</p> <p><b>Australia Market</b> 10:00-10:15   Keynote Presentation – Australian Biotech Overview: Trend, Popular Exits, and New Model <b>Speaker:</b> <a href="#">Betty Zhang, Boson Ventures, Investment Manager (Healthcare)</a> 10:15-11:00   Panel Discussion: How Biotech start ups can navigate cross-border collaboration between China and Australia <b>Moderator:</b> <a href="#">Betty Zhang, Boson Ventures, Investment Manager (Healthcare)</a> <b>Panelists:</b> Professor Jian Li, Biomedicine Discovery Institute, Monash University, Professor &amp; Head of the Antimicrobial Systems Pharmacology Laboratory Dr. Anne Laure Puaux, Walter and Eliza Hall Institute (WEHI), CEO, WEHI Ventures &amp; Head of BD, WEHI Dr Marthe D'Ombrain, CSL, Executive Director and Head of Global Research Innovation Stuart Dignam, MTPConnect, CEO Dr. Anush Rajapaska, Misti, Founder &amp; CEO</p>	<p><b>Asia Market</b> 09:00-09:10   Opening Presentation <b>Speaker:</b> <a href="#">Yunke Song, Syneos Health, Managing Director of Consulting</a> 09:10-09:50   Pharma Strategic Alliance Panel <b>Moderator:</b> <a href="#">Douglas Campbell, Mochida Pharmaceutical, Principal Scientist &amp; Senior Staff, R&amp;D Alliances</a> <b>Panelists:</b> <a href="#">Seunghwan Song, Chugai Pharmaceutical, Senior Manager, Global Business Analyst</a> 09:50-10:50   CGT Panel <b>Panelists:</b> <a href="#">Hiroshi Yamaguchi, Greenstaff Life Science (ICG Medical), Global Head of Life Science</a> Kobayashi Miho, ADL, Manager Blumenthal Yukari, Astellas, Gene Therapy Director Yoshiyuki Saito, N-of-One Pharmaceuticals Inc., CEO &amp; Founder</p>	<p><b>Middle East Market</b> 9:00-9:20   Keynote Presentation – Middle East Ecosystem Landscape <b>Speaker:</b> <a href="#">Haytham alRashed, Unifusion Business Service Co, Managing Director and Regulatory Affairs Head</a> 9:20-10:00   Panel Discussion: Regional Regulations, market entry strategies, and pharma business development in Middle East <b>Moderator:</b> <a href="#">Lulu Manassee, Alnylam Pharmaceuticals, Inc, Business Consultant and Principal Associate Scientist</a> <b>Panelists:</b> <a href="#">Joe Henein, NewBridge Pharmaceuticals, President and CEO</a> Hosam Dib, Bioscience Pharma, CEO Kareem S. Darwazah, Hikma Pharmaceuticals, VP, BD &amp; Alliance Management – MENA Mohammed Jobran, PharmaKnowl Consulting, Regulatory Affairs Consultant, CEO &amp; Principal Consultant</p> <p><b>LATAM Market</b> 10:00-11:00   Panel Discussion: Focus Business Development, Licensing, and Collaboration Opportunities with Latin American Pharma Companies <b>Panelists:</b> <a href="#">Joao Siffert, Eurofarm, Head of R&amp;D, CEO, Director</a> Juan, Vigenius, Founder Dr. Dhaval Soneji, Gan &amp; Lee Pharmaceuticals, Director Paulo Fernandes, AZD CRO   A2Z Clinical Research Site, Chief Operating Officer Lisa Palla Tavolaro, FAXE Group – Logistics for Clinical Trials, Global Director, Business Development</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>Korea Market</b> <b>Opening Session- China and Korea Collaboration &amp; Investment – Opportunities and Highlights</b> 12:00-12:20   Keynote Presentation - Highlight Capital (Korea &amp; China) <b>Speaker:</b> <a href="#">Lee, Highlight Capital, Principal</a> 12:20-13:00   Panel Discussion – China-Korea Collaboration Opportunities <b>Moderator:</b> <a href="#">Lee, Highlight Capital, Principal</a> <b>Panelists:</b> <a href="#">Soyong Jang, Celltrion Inc, R&amp;D Business Development Director</a> Hun Kim, SK Bioscience, President Dr. Sungwan Hwang, SK Biopharmaceutical, CTO 13:00 – 13:20   Keynote Presentation –ITP 13:20 – 13:40   Keynote Presentation <b>Speaker:</b> <a href="#">KHIDI China</a> 13:40 – 14:00   Keynote Presentation</p>	<p><b>Emerging Markets &amp; Belt and Road Regions</b> 12:00-12:20   Opening Keynote-Innovation Licensing &amp; Cross-Border Collaboration Opportunities <b>Speaker:</b> <a href="#">Mayur Sangwai, Dr. Reddy's Laboratories, Head of BD – Innovation Licensing</a> 12:20-13:10   Panel Discussion-Belt and Road Regions: BD, Licensing &amp; Manufacturing Opportunities in the China Market <b>Panelists:</b> <a href="#">Mayur Sangwai, Dr. Reddy's Laboratories, Head of BD – Innovation Licensing</a> Lama A. Shatara, Hikma Pharmaceuticals, Sr. Director, BD &amp; Alliance Management – MENA Songpon Deechongkit, Ph.D., Siam Bioscience Company Limited, CEO 13:10-14:00   Panel Discussion- Regulatory Landscape &amp; Market Access in Emerging Belt and Road Regions <b>Moderator:</b> <a href="#">Julia Sardaryan, Smooth Drug Development, CEO</a> <b>Panelists:</b> <a href="#">Dr. Obaidullah, PhD, MPH, Drug Regulatory Authority of Pakistan (DRAP),CEO</a> Dr. Akhtar Abbas Khan, PhD, Drug Regulatory Authority of Pakistan (DRAP), Director and Head Pharmacy Services (Clinical Trials) and Pharmacovigilance Center Kamran Khan, Smooth Drug Development, BD Director</p>	
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	<p><b>Korea Market</b> <b>BD &amp; Licensing Collaboration and Innovation Models</b> 15:00 – 16:00   Panel Discussion – Biotech Collaboration: BD and Co-development Models <b>Moderator:</b> <a href="#">Marc Appel, Pacific Bridge, Managing Partner</a> <b>Panelists:</b> <a href="#">Nam-Gu Her, AIMED BIÖ, CEO</a> Nari Yun, GI Innovation, Vice president Paul Song, Genequantum Healthcare, CSO Tingke tang, Joincare pharmaceutical, Vice President</p> <p><b>Asia market</b> 16:00-16:20   Keynote Presentation 16:20-17:20   Panel Discussion – BD Collaboration between China and Other Asian Regions <b>Moderator:</b> <a href="#">Ling Tong, Buchang BioPharma, BD VP/ Head</a> <b>Panelists:</b> <a href="#">Mayur Sangwai, Dr. Reddy's Laboratories, Head BD - Innovation Licensing</a> Manoj Thombare, Sun Pharma Laboratories Ltd, Senior General Manager and Business Development &amp; Licensing Aniruddh Galgali, Cipla Limited, Head of Strategy, Projects, Licensing &amp; M&amp;A 17:20-18:00   Panel Discussion – Supply Chain Collaboration between China and Other Asian Regions <b>Panelist:</b> <a href="#">Dr. SAMBASHIVAD, Abhigna Biotech Pvt Ltd, Founder</a></p>	<p><b>Russia Market</b> 15:00-15:20   Opening Remarks 15:20-16:20   Panel Discussion- BD &amp; Licensing Announcements <b>Moderator:</b> <a href="#">Alexander Nozdrachev, Innovant Bio, Managing Partner</a> <b>Panelists:</b> <a href="#">Svetlana Gogoleva, JSC "Akrikhin", Head of BD &amp; Licensing</a> Svetlana Bolevsheva, Binnopharm Group, LLC, Strategy &amp; Business Development Director Alexandr Gorynin, Nizhpharm JSC, Head of M&amp;A BD&amp;L department Vadim Ryabokon, R-Pharm, Vice President of Strategic Project Development Sergey Morozov, PIQ-Pharma Group, Business Development Head Igor Volkov, Nanolek, Head of Business Development Igor Borisenko, R-Pharm, Retail Business Head 16:20-17:20   Innovation and Supply Chain collaboration <b>Panelist:</b> <a href="#">Vladimir Popov, ROSBIOTECH &amp; ESMAR Ltd., Professor &amp; CEO</a> 17:20- 17:40   Q&amp;A</p>	
Concurrent	March 12th–14th BIOCHINA2026Exhibition	March 12th–14th BiOPartnering 1V1Meetings	<a href="#">Back to Contents</a>

## BIOCHINA2026 Global Regulatory Forum

## BIOCHINA2026 Global Clinical Development Forum

## BIOCHINA2026 Innovative Formulation Development Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	<p><b>Post-BD Clinical Strategy</b>  <b>Planner:</b> Yongjiang Hei, CSPC Pharmaceutical Group, CMO  09:00-09:20   Presentation: Clinical Strategy After BD Transactions  09:20-09:40   Presentation: Global Clinical Regulatory Submission Strategies  <b>Speaker:</b> Yongjiang Hei, CSPC Pharmaceutical Group, CMO  09:40-10:00   Presentation: Key Considerations for MRCT Clinical Trials  10:00-11:00   Panel Discussion: Global Clinical Development Strategies for China's Innovative Drugs  <b>Panelists:</b> Yongjiang Hei, CSPC Pharmaceutical Group, CMO  Goh Ak Han, Simcere Pharmaceutical Group Limited, CMO  Wei Zhu, BioRay Pharmaceutical Co., Ltd., CMO  Ming Shi, Shanghai Hutchison Pharmaceuticals, CMO  Steve Chin, MediLink Therapeutics, CMO  Jin Li, Shanghai Henlius Biotech, Inc., Vice President, Regulatory Affairs</p>	<p><b>Antibody Drug Formulation Development, Inhalation Formulation Regulation and Process Innovation</b>  09:00-09:20   Presentation: From ADC to XDC — Challenges in Conjugated Drug Product Development  <b>Speaker:</b> Chunyan Jia, WuXi XDC, Head of Bioconjugate Product Development Team  09:20-09:40   Presentation: High- and Ultra-High Concentration Antibody Formulation Development  09:40-10:00   Presentation: Current Status of Inhalation Formulation Regulation  <b>Speaker:</b> Guiliang Chen, Shanghai Center for Drug Evaluation and Inspection, Chief Pharmacist  10:00-10:20   Presentation: Challenges in Developing Improved Inhalation Formulations and Industrialization Barriers  <b>Speaker:</b> ZhenBo Tong, Southeast University, Professor  10:20-10:40   Presentation: Dual-Chamber Lyophilized Formulation Technology  <b>Speaker:</b> Yan Jiang, VISEN Pharmaceuticals, Head of Formulation  10:40-11:00   Q&amp;A Session</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	12:00-14:00   WuXi AppTec Special Session	<p><b>Innovative Therapy: New Clinical Models</b>  <b>Planner:</b> Yongjiang Hei, CSPC Pharmaceutical Group, CMO  12:00-12:20   Presentation: Upgrading Clinical Study Design under the New IIT Regulations  12:20-12:40   Presentation: Global Expansion – International Multi-Center Clinical Collaboration Strategies for Innovative Therapies  12:40-13:00   Presentation: New Globally Successful Clinical Models: Integrated Practices in Canada  <b>Speaker:</b> Jennifer Lai, Consul and Trade Commissioner, Consulate General of Canada in Shanghai  13:00-14:00   Panel Discussion: Innovative Models and Challenges under the New IIT Regulations  <b>Panelists:</b> Huji Xu, Changzheng Hospital, Professor  Anbo Xiang, CSPC Pharmaceutical Group, President of Clinical Division &amp; Non-Oncology CMO  Limin Wen, Simnova, SVP  Zonghai Li, CARsgen, Founder&amp;CEO  Jie Chen, IASO BIO, CMO  Jinghua Zhao, Fosun Kairos, CMO</p>	<p><b>Novel Biologics</b>  12:00-12:20   Presentation: Research Progress and Technical Challenges of Long-Acting Peptide Formulations  <b>Speaker:</b> Xiaojun Zhang, CSPC Pharma, Director, 4th Pharmaceutics Institute, Beijing R&amp;D Center  12:20-12:40   Presentation: Strategies for Long-Acting Peptide Formulations  <b>Speaker:</b> Mingjiang Rong, Chengdu Peide Biopharmaceutical Co., Ltd., Chairman  12:40-13:00   Presentation: Application of Innovative Drug Solid Dispersion Formulation Development in Preclinical and Clinical Studies  <b>Speaker:</b> Kunlin Wang, Allorion Therapeutics, Senior Scientist, CMC</p>
14:00-15:00	Networking & Events	Networking & Events	<p><b>Formulation Production &amp; Aseptic Processing</b>  13:00-13:20   Presentation: Interpretation of the Latest Aseptic Appendix Policies  <b>Speaker:</b> Hongyu Tan, Senior Pharmaceutical GMP Expert, Former Core Inspector at CFDI  13:20-13:40   Presentation: Structure and Development of Enterprise CCS Documentation  <b>Speaker:</b> Weifeng Lu, Junshi Lingang site, Quality Head and Authorized Quality Representative  13:40-14:00   Presentation: Case Sharing on Facility Construction and Aseptic Inspection Readiness  14:00-15:00   Panel Discussion: Aseptic Process Validation, APS, and Aseptic Interventions  <b>Panelists:</b> Hongyu Tan, Senior Pharmaceutical GMP Expert, Former Core Inspector at CFDI  Ji Yu, TJ Biopharma, VP of Manufacturing</p>
15:00-18:00	<p><b>APAC &amp; Emerging Market Regulations</b>  15:00-16:00   Pakistan: Pharmaceutical Manufacturing and Regulatory Affairs  16:00-16:30   Presentation: Regulatory Oversight of Pharmaceutical and Biological Manufacturing in Indonesia  <b>Speaker:</b> Shanti Marlina Sibuea, Ph.D., Acting Director of Drugs, Narcotics, Psychotropics, and Precursors Production Control - BPOM  16:30-17:00   Panel Discussion: Topic TBC  <b>Moderator:</b> Ding Liu, Qilu BioPharma, Deputy General Manager  <b>Panelist:</b> Shanti Marlina Sibuea, Ph.D., Acting Director of Drugs, Narcotics, Psychotropics, and Precursors Production Control - BPOM  17:00-18:00   Saudi Arabia</p>	<p><b>AI-Driven Clinical Development</b>  <b>Planner:</b> Yongjiang Hei, CSPC Pharmaceutical Group, CMO  15:00-15:20   Presentation: AI-Enabled Digital Clinical Testing for Drugs: Exploring New Paths and Practices in Precision Medicine  <b>Speaker:</b> Zhong Pei, The First Affiliated Hospital of Sun Yat-sen University, Deputy Director, Department of Neurology  15:20-15:40   Presentation: Intelligent Electronic Medical Records – Clinical Data Value Extraction and Compliance Practices  15:40-16:00   Presentation: Virtual Clinical Trials Guided by Computational Medicine  <b>Speaker:</b> Yu Zhao, Phil Rivers Tech, Co-Founder &amp; Deputy Director, Turing-Darwin Lab  16:00-17:00   Panel Discussion: Cross-Industry Dialogue – Collaborative Innovation and Challenges in AI Clinical Trials  <b>Panelists:</b> Yu Zhao, Phil Rivers Tech, Co-Founder &amp; Deputy Director, Turing-Darwin Lab  Dr. Li Wang, Xuanzhu Biopharmaceutical Co., Ltd., CMO, deputy general manager  Xiaojing Sun, Pfizer, Head of Clinical Trial Solutions &amp; Strategy Team  17:00-18:00   Panel Discussion: Data-Driven Approaches – Integrating Electronic Medical Records with Real-World Evidence</p>	

# BIOCHINA2026 Global Core Therapeutic Areas Ecosystem Forum

## BIOCHINA 2026 Scientific Achievement Translation Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	<p><b>Neurological Disorders</b></p> <p><b>Planner:</b> Xianbo Zhou, AstraNeura, Co., LTD., Founder&amp;CEO</p> <p>09:00-09:20   Presentation: Targeting TRPM7 Channel-Enzyme to Treat Neurodegenerative Disorders</p> <p><b>Speaker:</b> Nashat Abumaria, Fudan University Shanghai Medical College, Independent Researcher, Institute of Brain Science</p> <p>09:20-09:40   Presentation: Research on Biomarkers in Alzheimer's Disease</p> <p><b>Speaker:</b> Jiong Shi, Vice President, First Affiliated Hospital of University of Science and Technology of China</p> <p>09:40-10:00   Presentation: Neuroinflammation and Central Nervous System Disorders: Mechanistic Exploration and Novel Intervention Strategies</p> <p>10:00-11:00   Panel Discussion: Breaking Through CNS Innovative Drug R&amp;D – From Targets to Commercialization: Synergies and Challenges</p> <p><b>Moderator:</b> Xianbo Zhou, AstraNeura, Co., LTD., Founder &amp; CEO</p> <p><b>Panelists:</b> Gary Tong, Takeda R&amp;D China and APAC Region, VP, Clinical Development Head Chenyang Wu, Pivotal BioVenture Partners, Investment Director POE-JOU CHEN, Cali Biosciences, Co-Founder and CEO Zhaomin Chen, SIBR, External Innovation Lead Jiong Shi, The First Affiliated Hospital of University of Science and Technology of China, Vice president</p>	<p>09:00-11:00   <b>Translational Practice of Biopharmaceutical Scientific Achievements</b></p> <p>09:00-09:20   Presentation: Overcoming the Challenges of Translating High-End Biopharma Achievements: IP Strategy and Value Realization Mechanisms at Guangzhou Laboratory</p> <p><b>Speaker:</b> Ping Liang, Guangzhou Laboratory, Director, Technology Transfer Department</p> <p>09:20-09:40   Presentation: The "Pharma University Plan" for Translating New Drug R&amp;D Achievements — Lessons from Typical Case Studies</p> <p><b>Speaker:</b> Weijun Zhao, Ph.D., Chinese Society of Toxicology, Assistant Researcher, Master's supervisor, Certified Toxicologist</p> <p>09:40-10:00   Presentation: Translating Scientific Achievements in Research Hospitals and Building Proof-of-Concept Service Systems</p> <p><b>Speaker:</b> Juan Lei, West China Medical Center, Sichuan Medical University, Director</p> <p>10:00-11:00   Panel Discussion: Bridging the "Last Mile" of Research Translation — Collaborative Innovation Between National Platforms and Universities/Hospitals</p> <p><b>Panelists:</b> Ping Liang, Guangzhou Laboratory, Director, Technology Transfer Department Weijun Zhao, Ph.D., Chinese Society of Toxicology, Assistant Researcher, Master's supervisor, Certified Toxicologist Juan Lei, West China Medical Center, Sichuan Medical University, Director Dr. Weijun Shen, Changping National Laboratory, Director of the Center for Translational Research</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>Oncology</b></p> <p>12:00-12:20   Presentation: Development of Universal Cancer Vaccines</p> <p><b>Speaker:</b> Yong Yang, China Pharmaceutical University, VP</p> <p>12:20-12:40   Presentation: TBC</p> <p>12:40-13:00   Presentation: Tumor Drug Resistance Mechanisms and Exploration of Combination Therapy Strategies</p> <p>13:00-14:00   Panel Discussion: Deepening Targets — Maximizing Clinical and Commercial Value</p> <p><b>Panelists:</b> Dr. Guoxiang Wu, Novartis, Founder, Chairman and CEO Zig LANG, Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd, Vice President</p>	<p><b>Metabolic Disease Drugs</b></p> <p>Research Session</p> <p>12:00-12:20   Presentation: GLP-1 Multi-Target "Arms Race" – In-Depth Analysis of MNC Strategies and How Domestic Novel Drugs Can Break Through Competition</p> <p><b>Speaker:</b> Weiwei Mi, DXY Insight Database, Head of Innovative Drug Data Dept.</p> <p>12:20-12:40   Presentation: TBC</p> <p><b>Speaker:</b> Linong Ji, Professor of Medicine at Peking University, Director of Peking University Diabetes Center</p> <p>12:40-13:00   Presentation: TBC</p> <p>13:00-14:00   Clinical Session</p> <p><b>Panelists:</b> Linong Ji, Professor of Medicine at Peking University, Director of Peking University Diabetes Center</p>	<p><b>Sharing Practical Entrepreneurship Experiences by Professors</b></p> <p><b>Planner:</b> Dr. Weijun Shen, Changping National Laboratory, Director of the Center for Translational Research</p> <p>12:00-12:20   Presentation: Molecular Glue Drugs: From Basic Research to Clinical Translation</p> <p><b>Speaker:</b> Yong Cang, Degron Therapeutics, Co-Founder &amp; CSO, Professor of ShanghaiTech University</p> <p>12:20-12:40   Presentation: The Entrepreneurial Journey of Shenxi Biotech</p> <p><b>Speaker:</b> Gong Chen, NeuExcell Therapeutics, Founder &amp; Chairman</p> <p>12:40-13:00   Case Sharing</p> <p>13:00-14:00   Translational Strategies and Practical Entrepreneurship of Professors</p> <p><b>Panelist:</b> Qingsong Zhu, 五针松医药, Co-Founder &amp; CEO</p>
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	<p><b>Bayer Session</b></p> <p>15:00-18:00 Cardiovascular &amp; Renal Diseases (Tentative)</p>	<p><b>Ophthalmic Diseases</b></p> <p>15:00-15:20   Presentation: Clinical Needs in Retinal Diseases</p> <p>15:20-15:40   Presentation: Clinical Needs in Ocular Surface Diseases</p> <p>15:40-16:00   Presentation: Clinical Progress and Challenges of Gene Therapy Applications in Ophthalmic Diseases</p> <p><b>Speaker:</b> Fenghua Wang, Innostellar Biotherapeutics Co.,Ltd, CEO</p> <p>16:00-16:20   Presentation: TBC</p> <p><b>Speaker:</b> Haidi Hu, Arctic Vision, Founder, Chairman &amp; CEO</p> <p>16:20-16:40   Presentation: TBC</p> <p><b>Speaker:</b> Jionguang Chen, Oculgen Biomed Ltd., Founder &amp; CEO</p> <p>16:40-17:40   Panel Discussion: Innovative Development in Ophthalmic Diseases</p> <p><b>Panelists:</b> Dr. Jack Wu, Ocusun Biotechnolog, CSO Dr. Hongwei Peng, Jingze Biopharma Chairman &amp; Founder Haidi Hu, Arctic Vision, Founder, Chairman &amp; CEO Jionguang Chen, Oculgen Biomed Ltd., Founder &amp; CEO</p>	<p><b>Back to Contents</b></p> <p><b>16</b></p>

# BIOCHINA 2026 Radiopharmaceutical Innovation Forum

# BIOCHINA 2026 Immunotherapy Innovation Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	<p><b>Future Exploration – Radiopharmaceutical Development from a BD Perspective</b>  <b>Planner:</b> Novartis  10:00-11:00   Panel Discussion: Next Waves in RLT Research and Business Development  <b>Moderator:</b> David Chen, BFC GROUP, Managing Director &amp; Co-Founder  <b>Panelists:</b> Shona Whyte, Novartis  Marcel Reichen, Ratio Therapeutics  Tao Yu, LAV, Principal  Zhibo Liu, Peking University, Professor, School of Chemistry and Molecular Engineering  Yunxia Yang, HongShan Capital Group, Partner</p>	<p><b>09:00-11:00   Immunotherapy Innovation</b>  <b>Planner:</b> Bing Su, Director, Shanghai Institute of Immunology  09:00-09:30   Presentation: Topic TBC  <b>Speaker:</b> Youqiong Ye, Shanghai Jiao Tong University School of Medicine, Principal Investigator  09:30-10:00   Presentation: Topic TBC  <b>Speaker:</b> Qiang Gao, Fudan University  10:00-10:30   Presentation: Mechanisms of Targeting Immune Checkpoints to Enhance Cancer Immunotherapeutic Efficacy  <b>Speaker:</b> Yan Zhang, Shanghai Jiao Tong University School of Medicine/Shanghai Institute of Immunology, Principal Investigator  10:30-11:00   Presentation: Topic TBC</p>	<p><b>Frontiers in Future Biopharma Forum</b>  <b>Planner:</b> Chen Dong, Chinese Academy of Sciences, Academician  09:00-09:30   Presentation: Constructing Spatiotemporal Proteomes and Virtual Cells to Support Drug Discovery  <b>Speaker:</b> Tiannan Guo, Westlake University School of Medicine, Tenure-track Associate Professor / Researcher  09:30-10:00   Presentation: TBC  <b>Speaker:</b> Ju-Sheng Zheng, Westlake University School of Medicine, Tenured Associate Professor / Researcher; Executive Vice Dean, School of Future Biomedicine  10:00-10:30   Presentation: TBC  <b>Speaker:</b> Chen Dong, Chinese Academy of Sciences, Academician  10:30-11:00   Presentation: The all-encompassing roles of innate immune receptor in health and diseases  <b>Speaker:</b> Jenny Ting, The University of North Carolina at Chapel Hill, Professor, Co-Founder of IMMvention Therapeutics</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>Innovative R&amp;D – Ligand Selection and Early-Stage Development</b>  <b>Planner:</b> Novartis  12:00-12:20   Presentation: Innovative Industrial Development of Radiopharmaceuticals – From Molecule to Clinic  <b>Speaker:</b> Ge Bai, Sinotau Pharmaceutical Group, Vice President  12:20-12:40   Presentation: Discovery of Bioactive Peptides and Their Applications in RDC Drugs  <b>Speaker:</b> Yilong Li, PepLib, Vice President  12:40-13:00   Presentation: VanKeur Targeted Radiopharmaceutical R&amp;D Platform (InnoRDC) and Project Updates  <b>Speaker:</b> Dr. Ning Xi, FindCure, CEO  13:00-13:20   Presentation: From Innovation to Clinic – Entering the Era of Integrated Precision Therapy: Development of Radioligand Conjugates  <b>Speaker:</b> Bo Shan, BoomRay, CEO  13:20-13:40   Presentation: Discovery of c-Met Targeted <math>^{111}\text{In}/^{225}\text{Ac}</math> Theranostic Radiopharmaceuticals  <b>Speaker:</b> Dr. Fa Liu, Full-Life Technologies, CSO  13:40-14:00   Presentation: Seamless Integration of Global FIC and China FIH to Empower Global RLT Innovation Collaboration  <b>Speaker:</b> Ivy Chao, C Ray Therapeutics</p>	<p><b>12:00-14:00   Autoimmune Diseases</b>  12:00-12:30   Presentation: Dermatology Research  <b>Speaker:</b> Michel Gilliet, CHUV Lausanne University Hospital, Chairman, 12:30-13:00   Presentation: From Red Ocean to Blue Ocean: Decoding High-Potential Targets for Autoimmune Therapy in China  <b>Speaker:</b> Zhong Zhao, DXY Insight Database, BU Head &amp; Chief Product Officer  13:00-14:00   Endocrine Diseases</p>	
14:00-15:00	Networking & Events	Networking & Events ( March 13 <sup>th</sup> )	
15:00-18:00	<p><b>Clinical Development – Precision Matching of Radionuclide Selection and Clinical Indications</b>  15:00-15:20   Presentation: Radionuclide Therapy for Thyroid Cancer and Other Diseases  <b>Speaker:</b> Hongcheng Shi, Director, Department of Nuclear Medicine, Zhongshan Hospital, Fudan University  15:20-15:40   Presentation: Frontiers and Clinical Translation of PSMA-Targeted Theranostics  <b>Speaker:</b> Shaoli Song, Fudan University Shanghai Cancer Center, Director of the Department of Nuclear Medicine  15:40-16:40   Panel Discussion: Practical Considerations in Radionuclide Selection and Clinical Matching  <b>Panelists:</b> Jianjun Chen, Ph.D., StarRay Therapeutics, President &amp; CSO  Hongcheng Shi, Zhongshan Hospital, Fudan University, Director, Department of Nuclear Medicine  Shaoli Song, Fudan University Shanghai Cancer Center, Director of the Department of Nuclear Medicine  <b>Future Manufacturing – Radiopharmaceutical CMC &amp; Industrialization</b>  16:40-17:40   Future Commercialization Strategies for Radiopharmaceuticals  <b>Panelists:</b> Tao Xu, Ph.D., Suzhou SmartNuclide, Founder &amp; CEO  Bo Shan, BoomRay, CEO  Min Hong, JunKangLiTai Biosciences, General Manager  Susan Wang, Nuruit Medical Technology Co., Ltd., CBO  Zheng Wang, TheraNosta Inc, CEO</p>	<p><b>Treg Nobel Prize Forum</b>  <b>Planner:</b> Bin Li, Ph.D., Shanghai Institute of Immunology, Senior Investigator &amp; Associate Director  15:00-15:05   Opening Remarks  <b>Speaker:</b> Bin Li, Ph.D., Shanghai Institute of Immunology, Senior Investigator &amp; Associate Director  15:05-15:25   Presentation: Advances in Basic and Clinical Research of Regulatory T Cells (Treg)  <b>Speaker:</b> Songguo Zheng, Shanghai Jiao Tong University, Chair Professor &amp; Dean, School of Cell and Gene Therapy  15:25-15:45   Presentation: Significance of Identifying and Validating Circulating Treg fci Subtypes/States in Non-Small Cell Lung Cancer Patients Using Single-Cell Analysis  <b>Speaker:</b> Xiangdong Wang, Fudan University Affiliated Zhongshan Hospital, Distinguished Professor  15:45-16:05   Presentation: From "Immune Balance" to "Immune Oscillation" — 2025 Nobel-Winning Treg Discoveries and Future Perspectives  <b>Speaker:</b> Bin Li, Ph.D., Shanghai Institute of Immunology, Senior Investigator &amp; Associate Director  16:05-16:25   Presentation: Treg Therapy — From Mechanistic Studies to Clinical Translation  <b>Speaker:</b> Ling Lv, Kuzhou Medical University, Vice President  16:25-16:45   Presentation: Targeting Treg Cell Survival and Death — Overcoming Bottlenecks in Autoimmune and Neurodegenerative Disease Therapies  <b>Speaker:</b> Chengyu Zou, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Principal Investigator  <b>Future Translation of Treg Research</b>  16:45-17:05   Presentation: Clinical Translation of Nobel-Winning Projects  <b>Speaker:</b> Mingqi Lv, Novabio Therapeutics, CEO  17:05-17:25   Presentation: To Be Confirmed  <b>Speaker:</b> Yanjing Su, MaRiNA BioTech, Founder  17:25-18:00   Panel Discussion: Innovative Translation of Treg Research  <b>Panelists:</b> Dr. Tony Liu, Benethera Biotechnology Co.,Ltd., COO  Yanjing Su, MaRiNA BioTech, Founder  Feng Yang, Blue Ocean Capital, Founder  Mingqi Lv, Novabio Therapeutics, CEO</p>	<p><b>Back to Contents</b></p>

# BIOCHINA 2026 Global Supply Chain Innovation Forum

# BIOCHINA2026 CMC Global Expansion Forum

# BIOCHINA 2026 Global Technology Transfer & Compliant Manufacturing Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	<b>Europe &amp; North America Market</b> 09:00-11:00   Thermo Fisher Special Session 09:00-10:00   Trends in Biopharmaceutical Global Expansion – From R&D to Manufacturing 10:00-11:00   Presentation: Regulatory Submission and Market Entry Strategies Based on China, US, and EU Guidelines <ul style="list-style-type: none"> <li>• Raw Material Selection</li> <li>• Building Domestic Manufacturing Quality Systems</li> <li>• Considerations in Clinical Trial Design and Other Aspects</li> </ul>	<b>Technology Transfer and Compliant Manufacturing for Global Expansion Projects</b> 09:00-09:20   Presentation: Elevating Quality and Compliance Standards: Operational Excellence through the Synergy of GMP and GDP Regulatory Intelligence <b>Speaker:</b> Dr Dinesh Khokal, BeOne Medicines Singapore, Global Director, GxP Surveillance & External Affairs, Global Quality Management Systems 09:20-09:40   Presentation: Topic TBC <b>Speaker:</b> Bo Wang, Johnson & Johnson, Senior Manager, Clinical Supply Chain Quality 09:40-10:00   Presentation: Brief Discussion on Drug Serialization for Overseas Markets <b>Speaker:</b> Yu Jiang, Suzhou UnionBiopharm Biosciences Co.,Ltd., DP Director 10:00-11:00   Panel Discussion: Early-Stage Technology Transfer Planning in Project Development <b>Panelist:</b> Feng Hou, Qilu Pharmaceutical, Technical Operations Director
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<b>Global Supply Chain Development</b> 12:00-12:20   Presentation: Challenges of High-Frequency International Expansion on Supply Chain Development <b>Speaker:</b> Fangfang Ma, Henlius Biotech, Supply Chain Executive Director 12:20-12:40   Presentation: Design and Build the Right Supply Chain for Global Success <b>Speaker:</b> Dr. Frank Binder, GSCA, Global Supply Chain Advisors 12:40-13:00   Presentation: International Cold Chain and Transportation Services 13:00-14:00   Panel Discussion: Global Supply Chain Strategies <b>Panelists:</b> Rong Tan, Novartis, Supply Chain Director Fangfang Ma, Henlius Biotech, Supply Chain Executive Director	<b>CMC Global Expansion</b> 12:00-13:00   Panel Discussion: Product Global Expansion Planning and Process Considerations <b>Moderator:</b> Shengchang Xu, Henlius Biotech, SVP&CTO <b>Panelist:</b> Hua Xie, Duoning Biotech, SVP Xiaoming Yang, RemeGen, CMO Kai Gao, Asymchem Laboratories, CTO Weichang Zhou, MediLink Therapeutics, CTO 13:00-13:20   Presentation: On-Site Inspections and Case Sharing of Biologics by FDA, EMA, and PIC/S <b>Speaker:</b> Shi Bai, TopAilance, Suzhou UnionBiopharm Biosciences Co.,Ltd., VP of Quality 13:20-13:40   Presentation: Key Focus Areas of UAE Inspectors in Antibody Drug Manufacturing Inspections <b>Speaker:</b> Bing Tu, Zhejiang Provincial Drug Inspection Center, Biological Products Inspector 13:40-14:00   Presentation: Capturing Global Growth Markets: Registration Strategies and Implementation Pathways for Biologics along the "Belt and Road" <b>Speaker:</b> Chengde Zheng, Mabwell (Shanghai) Bioscience, RA head	<b>Regulatory Submission and Inspection</b> 12:00-12:20   Presentation: INVIMA GMP Audit Process and Key Considerations for Biologics Export to Colombia <b>Speaker:</b> Hu Dai, Jiangsu T-mab Biopharmaceutical Co., Ltd, Head of quality & QP 12:20-12:40   Presentation: On-Site Inspection Preparedness for Antibody Drugs <b>Speaker:</b> Shiming Yang, Bubu Biopharmaceutical, Production Director 12:40-13:00   Presentation: Data Integrity and Case Studies in Domestic/International Manufacturing Inspections <b>Speaker:</b> John Loeng, GeneScience Pharmaceuticals, Executive Director, Clinical Quality Assurance 13:00-14:00   Panel Discussion: CMC System Establishment and Domestic/International Inspection for Large-Scale Manufacturing <b>Moderator:</b> Jianjun Luo, WuXi XDC, VP & Head of Conjugated Formulation Development and Manufacturing <b>Panelist:</b> Ding Liu, Qilu BioPharma, Deputy General Manager Haijun Wu, Alphamab Oncology, SVP Juping Shen, CANbridge Pharmaceuticals, SVP Jianjun Luo, WuXi XDC, VP & Head of Conjugate Formulation Development and Manufacturing
14:00-15:00	Networking & Events	Networking & Events	<b>Commercial Manufacturing</b> 14:00-14:20   Presentation: Challenges and Considerations Before Commercial Manufacturing from a Process Validation Perspective <b>Speaker:</b> An Wang, Shanghai Langrun Mabwell Biomedical Technology Co., Ltd, Quality Head 14:20-14:40   Presentation: Biologics Process Validation under the QBD Concept <b>Speaker:</b> Junwei Li, Lunan Pharmaceutical, Production Director 14:40-15:00   Presentation: Future Manufacturing – Smart Biopharmaceutical Factories 15:00-15:20   Presentation: Multi-Product Shared-Line Manufacturing 15:20-15:40   Presentation: Raw Materials and Supply Chain Management in Commercial Manufacturing 15:40-16:00   Q&A / Discussion
15:00-18:00	<b>Local Supply Chain Development</b> 15:00-15:20   Presentation: CDMO Supply Chain Development and Management for Cell & Gene Therapy <b>Speaker:</b> Hui Chen, Porton Advanced, CEO & Porton Pharma, CFO 15:20-15:40   Presentation: Establishing a Biologics Supply Chain System <b>Speaker:</b> Yilong Xie, Chia Tai Tianqing, Supply Chain Director 15:40-16:00   Presentation: Supply Chain Construction and Management Challenges in CXO Companies <b>Speaker:</b> Jie Shang, Chime Biologics, Supply Chain Director 16:00-16:20   Presentation: Supplier Management and Supply Chain Organizational Collaboration Strategies <b>Speaker:</b> Jinxia Jia, Remegen.cn, Supply Chain Management Department, Executive Director 16:20-17:00   Panel Discussion: Innovations in Supply Chain Management <b>Panelists:</b> Haixia Gao, Shanghai Cell Therapy Group, Senior Director of Supply Chain Jinxia Jia, Remegen.cn, Supply Chain Management Department, Executive Director Yilong Xie, Chia Tai Tianqing, Supply Chain Director Xunbing Yan, Revvity, Head of Reagents Procurement, China <b>Case Studies in Supply Chain Management</b> 17:00-17:20   Presentation: Laboratory Reagents and Consumables Procurement Strategies <b>Speaker:</b> Yanting Tong, Junshi Biosciences, Senior Purchasing Manager 17:20-17:40   Presentation: Supplier Performance Management Across All Categories <b>Speaker:</b> Hailong Zhang, Juventas Cell Therapy, Senior Manager, Strategic Sourcing 17:40-18:00   Presentation: Localization of Key Materials in Import Transfer Projects <b>Speaker:</b> Xunbing Yan, Revvity, Head of Reagents Procurement, China	<b>CMC Global Expansion – Panel Discussion</b> 15:00-16:00   Panel Discussion: Quality Systems and Global Compliance <b>Moderator:</b> Ruliang Zhang, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Senior VP and Deputy GM <b>Panelist:</b> Dongming Wang, Innoven Biologics, Senior Vice President <b>Global Regulatory Submission</b> 16:00-16:20   Presentation: IND-Stage Regulatory Submission Strategies for China, US, and EU Markets <b>Speaker:</b> Na Xu, Essex Bio-Technology Ltd., AVP & Head of Regulatory Affairs 16:20-16:40   Presentation: Common Regulatory Recognitions and Accelerated Programs in Drug Development for China and the US <b>Speaker:</b> Andy Yang, Elipsience, RA Head, Director 16:40-17:00   Presentation: Post-Approval Pharmaceutical Change Management for Biologics in Europe and the US 17:00-18:00   Panel Discussion: Domestic and International Pharmaceutical Regulatory Submission and Change Management <b>Panelist:</b> Jianwen Li, SinoCellTech, Head of Regulatory Affairs	<b>Back to Contents</b> <span style="float: right;">18</span>

# BIOCHINA2026 Innovative Process Technology Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	<p><b>Process Development &amp; PPQ</b> 10:00-11:00   Panel Discussion: Antibody Process Development and PPQ Process Validation <b>Moderator:</b> Xianli Su, Qilu Pharmaceutical, Lead of Manufacturing Science and Technology <b>Panelists:</b> Zhiqiang Chen, D3 Bio, Head of CMC Bingbing Wang, TJ Biopharma, Director of Technical Operations Yefei Wang, Gmax Biopharm LLC., Vice President Xin Xin, MediLink Therapeutics, Executive Director of CMC Operations Management Guiling Jia, Chengqi Zhizao (Beijing) Technology Co., Ltd., Founder &amp; CEO</p>	<p><b>Title Sponsor:</b> Sunresin New Materials Co.,Ltd. <b>Purification Processes and Digital Intelligence Empowerment</b> 09:00-09:20   Presentation: Chromatography Resins <b>Speaker:</b> Qiang Chen, DanausGT BioTechnology, CTO 09:20-09:40   Presentation: Topic TBD <b>Speaker:</b> Sunresin New Materials Co.,Ltd. 09:40-10:00   Presentation: Empowering Continuous Biopharmaceutical Manufacturing with Digital Intelligence <b>Speaker:</b> Dongqiang Lin, Zhejiang University, Professor of College of Chemical and Biological Engineering 10:00-11:00   Panel Discussion: How Artificial Intelligence Drives Innovation in Biopharmaceutical Downstream Processes: Case Studies, Challenges, and Future Directions <b>Moderator:</b> Yan Fang, Qilu Pharmaceutical Company, Senior Director <b>Panelists:</b> Dr. Dongmei Han, Henlius, General Manager of Process Development Dongqiang Lin, College of Chemical and Biological Engineering, Zhejiang University, Professor</p>	<p><b>ADC Process Development</b> 09:00-09:20   Presentation: CMC Research on Bispecific ADCs <b>Speaker:</b> Xiaojing Gong, InnolakeBio, Associate Director, CMC 09:20-09:40   Presentation: Early-Stage Process Development of ADCs: Studies and Key Considerations <b>Speaker:</b> Dr. Wenjie Shao, Gan&amp;Lee Pharmaceutical Inc., Executive Director 09:40-10:00   Presentation: ADC Process Characterization and Process Validation 10:00-11:00   Panel Discussion: Implementation of ADC CMC Development Strategies and Globalization Pathways <b>Panelists:</b> Min Zhao, Phrontline Biopharma, VP Jianxin Chen, Zencore Biologics, CEO Jianqiu Mi, Nanomicro Technology, Deputy General Manager</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>ADC Quality and Regulatory Submission</b> 12:00-12:20   Presentation: Key Considerations for ADC Regulatory Submissions <b>Speaker:</b> Xuejing Yao, Shanghai Pharmaceuticals, Head of ADC Early Research, Central Research Institute &amp; General Manager, Quality Department 12:20-12:40   Presentation: Quality Research of ADC Drugs <b>Speaker:</b> Lingrui Li, Lepu Biopharma, Associate Director, Analytics 12:40-13:00   Presentation: Strategies and Case Studies for Complex Molecule Quality Analysis <b>Speaker:</b> Wen Li, XDC, Associate Director</p> <p><b>13:00-14:00   Agilent Special Session</b> 13:00-13:30   Presentation: Application and Progress of Multi-Platform Characterization for ADCs <b>Speaker:</b> Min Xia, Agilent, Biopharmaceutical Technology Specialist 13:30-14:00   Presentation: High-Throughput Capillary Electrophoresis Enabling Rapid Development of Next-Generation Antibody Drugs <b>Speaker:</b> Hao Chen, Agilent, Genomics Technology Specialist</p>	<p><b>Antibody CMC Development and Management Session</b> 12:00-12:20   Presentation: Challenges and Strategy Adjustments in Process Development for Different Types of Large Molecule Drugs <b>Speaker:</b> Jingjing Lin, Livzon Mabpharm, Director, Process Development 12:20-12:40   Presentation: Considerations in Upstream Process Development for Antibody Drugs <b>Speaker:</b> Yanwen Bao, Halobio, Deputy Director 12:40-13:00   Presentation: Antibody Process Characterization <b>Speaker:</b> Chao Yu, Shanghai Pharmaceuticals, Production Director</p> <p><b>13:00-14:00   Lisure Technology Special Session</b> 13:00-13:50   Presentation: LetsGo3.1 (M++): Direct Application – One-Stop Downstream Process Solution for Clinical Production <b>Speaker:</b> Zuwei Jin, Lisure (USA), General Manager 13:50-14:00   Q&amp;A</p>	<p><b>Analytical Testing and Quality Management</b> 12:00-12:40   Panel Discussion: Challenges and Breakthroughs in Quality Control and Analytical Testing of Biologics: From Pharmacopeial Standards to End-to-End Quality Control Across R&amp;D and Manufacturing <b>Panelists:</b> Chen Gang, Shanghai Institute for Drug Control (SIFDC), Chief Pharmacist Fei Wang, Shanghai Applied Protein Technology Co., Ltd., Technical Director 13:00-13:20   Presentation: Overview of Updates and Revisions to Biological Analytical Methods in the 2025 Edition of the Chinese Pharmacopoeia (Volume III) <b>Speaker:</b> Chen Gang, Shanghai Institute for Drug Control (SIFDC), Chief Pharmacist 13:20-13:40   Presentation: Establishment and Implementation of Quality Management Systems <b>Speaker:</b> Dehua Shen, Zai Lab, Deputy Director of Quality 13:40-14:00   Presentation: Process Residuals: Quality Control and Analytical Strategies <b>Speaker:</b> Lin Bian, Genrix Biopharmaceutical, Associate Director, Quality Control 14:00-14:20   Presentation: From Process to Product: Quality Control and Analytical Approaches Across MSC-sEV Therapeutic Development <b>Speaker:</b> Shuangshuang Yang, Shandong Qilu Cell Therapy Engineering Technology Co., Ltd., R&amp;D Project Manager</p>
14:00-15:00	Networking & Events	Networking & Events	<p>14:20-14:40   Presentation: Oligonucleotide Drugs <b>Speaker:</b> Yanshan Lu, Youjia (Hangzhou) Biomedical Technology Co., Ltd., Deputy General Manager / Quality Director</p>
15:00-18:00	<p><b>Cell Line Development &amp; Construction</b> 15:00-15:20   Presentation: Antibody Expression Vectors / CHO High-Expression Cell Line Construction <b>Speaker:</b> Dr. Zhiwei Song, Nexa Biologics, Singapore, CSO 15:20-15:40   Presentation: Flexible and Rapid Cell Line Development Platform Applicable to Multiple Protein Types <b>Speaker:</b> Zichen Qian, RemeGen, Director of Process Development 15:40-16:00   Presentation: Toward high-antibody-producing CHO cell lines: from random to targeted integration technologies <b>Speaker:</b> Yuansheng Yang, Bioprocessing Technology Institute, Senior Principal Scientist</p> <p><b>16:00-17:00   Swiss Bio Biologics Special Session</b> 16:00-16:45   Presentation: Engineering Efficiency: Advanced Bioreactor Concepts for Sustainable Bioprocessing <b>Speaker:</b> Kurt Ever, Bioengineering AG, Head of Innovation 16:45-17:00   Q&amp;A 17:00-18:00   Panel Discussion: Construction and Culture Optimization of High-Producing Bispecific/Multispecific Antibody Cell Lines <b>Moderator:</b> Xi Chen, Qilu Pharmaceutical, Director, Cell Engineering <b>Speaker:</b> Dr Song Zhiwei, NexaBiologics, Singapore, CSO Yuansheng Yang, Bioprocessing Technology Institute, Senior Principal Scientist Zichen Qian, RemeGen, Director of Process Development</p>	<p><b>Sponsored Session: Cytiva</b> <b>Downstream Process Development for Antibodies</b> <b>Planner:</b> Hao Li, Hutchison Whampoa, VP 15:00-15:20   Presentation: Process Design and Robust Scale-Up for "Abnormal Yield" Projects <b>Speaker:</b> Weifeng Chen, Mabgen Biotech, Senior Manager, Purification Process Development 15:20-15:40   Presentation: Strategies for Efficient Operation of Antibody Purification Processes at 10,000-L Scale <b>Speaker:</b> Weiwei Hu, Chia Tai Tianqing, Head of Manufacturing 15:40-16:00   Presentation: Application of In Silico Modeling in Downstream Chromatography Process Development <b>Speaker:</b> Zijun Su, BeOne Medicines, Downstream Process Manager 16:00-16:20   Presentation: Application of AI PSO Algorithm in Downstream Process Development <b>Speaker:</b> Yuwen Zhu, BeOne Medicines, Senior Scientist 16:20-16:40   Presentation: Topic TBC <b>Speaker:</b> Cytiva 16:40-17:40   Panel Discussion: CMC Development and Lifecycle Management of Antibody Drugs under Global Compliance <b>Moderator:</b> Hao Li, Hutchison Whampoa Limited, VP <b>Panelists:</b> KarenTwu, Hutchmed, VP Guanhua Wang, Elpiscience Biopharma, CMC VP</p>	<p>14:40-15:00   Presentation: CAR-T / Gene Therapy 15:00-15:20   Presentation: Peptides 15:20-15:40   Presentation: Small Molecules 15:40-16:00   Q&amp;A / Discussion</p>

# BIOCHINA2026 Small Molecule Drug Innovation Forum

# BIOCHINA 2026 AI for Science Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	<p><b>Opening Panel Discussion</b> 10:00-11:00   Panel Discussion: Innovation Breakthroughs in Small-Molecule Drugs from a Researcher's Perspective</p> <p><b>Moderator:</b> Li Chen, Hua Medicine (Shanghai) Ltd., CEO <b>Panelists:</b> Donghui Qin, Pheno Therapeutics, Chairman &amp; CEO John Yu, CGeneTech(Suzhou,China)Co.,Ltd., CEO Yuanwei Chen, Hinova Pharmaceuticals Founder &amp; Chairman Yusheng Wu, Ph.D., TYK Medicines, Inc. Chairman of Board &amp; CEO Qun Dang, Genuine Biotech, Executive Director, President &amp; Chief Business Officer (CBO)</p>	<p><b>Clinical Indication Development – Oncology Drugs</b> 09:00-09:40   09:00-09:40   Panel Discussion: Oncology Drug Development</p> <p><b>Moderator:</b> Li Zeng, Jins Medical Science And Technology (Shanghai) Co., Ltd., CEO <b>Panelists:</b> Fugen Li, Translational Medicine HaiHe Pharmaceutics Inc., SVP Song Liu, SynRx Therapeutics, CEO</p> <p>09:40-10:00   Presentation: Development of Second-Generation PARP Inhibitors</p> <p><b>Speaker:</b> Dr. Li Wang, Xuanzhu Biopharmaceutical Co., Ltd., CMO, Deputy General Manager</p> <p>10:00-10:20   Presentation: Enabling Patient Access to Targeted Therapies with Rapid and Accessible NGS CDx Solution</p> <p><b>Speaker:</b> Daisy Sun, Thermo Fisher Scientific, Diagnostics Partnering China Lead</p> <p>10:20-10:40   Presentation: Developing AMX3009: Optimal Therapy for Non-Classic PACC-Mutant Lung Cancer</p> <p><b>Speaker:</b> Dr. Jian Hong, Arromax Pharmaceutical, General Manager &amp; Co-Founder</p> <p>10:40-11:00   Presentation: Top 25 Translational Medicine Targets in 2025 (Early-Stage Drug Development)</p> <p><b>Speaker:</b> Xihong Hu, PharmCube, Senior Researcher</p>	<p><b>Basic Research and Core Technology Integration</b> 09:00-09:30   Presentation: Multimodal Biological Foundation Models for Disease Mechanism Exploration (Title TBD)</p> <p><b>Speaker:</b> Luyi Tian, Guangzhou Laboratory, Researcher</p> <p>09:30-10:00   Presentation: Digital Cell Foundation Models Empowering Drug Target Discovery</p> <p><b>Speaker:</b> Xin Li, Institute of Zoology, Chinese Academy of Sciences &amp; Beijing Institute for Stem Cell and Regenerative Medicine, Joint-appointed Researcher</p> <p>10:00-10:30   Presentation: Title TBD</p> <p>10:30-11:00   Presentation: What Is Still Missing in Biomedical AI? From "Data Volume" to "Data Usability"</p> <p><b>Speaker:</b> Shengce Tao, Shanghai Institute of Systems Biomedicine, Shanghai Jiao Tong University, Vice Dean &amp; Professor</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>Innovative Drug Development &amp; Global Expansion</b> 12:00-13:00   Panel Discussion: Technology and Market-Driven Diversified Collaborations in Small Molecule Innovative Drugs</p> <p><b>Panelists:</b> Xiang Li, Xellsmart, CEO Chun Liang, Enkang Pharmaceuticals, Professor, Hong Kong University of Science and Technology &amp; Founder &amp; CSO, Enkang Pharmaceuticals Jane Wang, Salubris Pharmaceuticals, CSO Dr. Liping Liu, HighTide, Founder &amp; CEO</p> <p>13:00-13:20   Presentation: Breakthrough and Renewal — Innovative Clinical Development Strategies for Small Molecule Drugs</p> <p><b>Speaker:</b> Sumei Liu, Hengrui Pharmaceuticals, Senior Medical Director</p> <p>13:20-14:00   Panel Discussion: Innovative Development of Small-Molecule Drugs from a Clinical Perspective</p> <p><b>Panelists:</b> Liu Yang, Allorion Therapeutics, VP, Clinical Development Yilin Li, Zhengxiang Pharmaceutical, CMO Jiahong Zhao, CGeneTech(Suzhou,China)Co.,Ltd., CMO Xiaoning Guo, HaiHe Pharmaceutical, CMO</p>	<p><b>Clinical Indication Development – Multi-Indication</b> 12:00-12:20   Presentation: Preclinical Exploration of FIC Three-Target Small Molecule Innovative Drugs in Autoimmune Diseases</p> <p><b>Speaker:</b> Xiaohong Yu, Fosun Pharma and Chairman of Novaonco Co., Ltd., Co-CSO</p> <p>12:20-13:00   Panel Discussion: Case Sharing on Autoimmune Drug Development</p> <p><b>Panelists:</b> Yang Song, Hygria Therapeutics, Fosun Pharma Global R&amp;D, Vice President, Head of I&amp;I, CEO Shuihua Zhang, NewDEL Biotech, Deputy General Manager Karen Liu, Ph.D., 3E Bioventures Capital, Founding Partner Thermo Fisher</p> <p>13:00-13:20   Presentation: Ifogrel (CG-0255) Development Case: Best-in-Class Anti-Platelet Drug Addressing Cardiovascular and Cerebrovascular Clinical Gaps</p> <p><b>Speaker:</b> XiaoWu Chen, Shanghai CureGene Pharmaceutical Co., Vice President, Chemistry</p> <p>13:20-13:40   Presentation: Antiviral Drug Development</p> <p><b>Speaker:</b> Hejun Lv, Ark Biopharmaceutical, CSO</p> <p>13:40-14:00   Presentation: TBC</p> <p><b>Speaker:</b> Lei Li, Jiayue Pharmaceutical, Deputy General Manager, Innovative Development &amp; External Collaboration</p>	<p><b>Drug Discovery and Clinical Translation Session</b> 12:00-12:30   Presentation: AI-driven Small Molecule Generation Algorithms and Precision Drug Design (Title TBC)</p> <p><b>Speaker:</b> Hongming Chen, Guangzhou Laboratory, Researcher</p> <p>12:30-13:00   Presentation: Key Technologies for Original Nucleic Acid Drugs and Clinical Translation Research (Title TBC)</p> <p><b>Speaker:</b> Zhihao Han, China Pharmaceutical University, Associate Researcher</p> <p>13:00-13:30   Presentation</p>
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	<p><b>Breakthroughs and Challenges in "Undruggable" Targets</b> 15:00-16:00   Ice Bioscience Special Session</p> <p>15:00-15:30   Presentation: Dual Payload ADC (Tentative)</p> <p><b>Speaker:</b> Li Li, Ice Bioscience, VP</p> <p>15:30-16:00   Presentation: TBC</p> <p><b>Speaker:</b> Xiaojian Wang, Ice Bioscience, Senior Director</p> <p><b>Planner:</b> Lihui Zou, Degron Therapeutics, CEO</p> <p>16:00-17:00   Panel Discussion: Overcoming the "Undruggable" Challenge</p> <p><b>Panelists:</b> Lihui Zou, Degron Therapeutics, CEO WeiWen Ying, Ranok Therapeutics(Hangzhou) Co., Ltd., CEO Xinghua Hu, Rapafusyn, CEO LI XING, LexBio Therapeutics, CEO</p> <p>17:00-17:20   Presentation: Prospecting for the Undruggable TNFR1 Antagonist</p> <p><b>Speaker:</b> Yuan Liu, University of Pittsburgh, Associate Professor of Medicine</p> <p><b>Molecular Glue Session</b> 17:20-17:40   Presentation: RapaGlues—A Non-degrading Molecular Glue Platform for Undruggable Disease Targets</p> <p><b>Speaker:</b> Xinghua Hu, Rapafusyn, CEO</p> <p>17:40-18:00   Presentation: First-In-Class Molecular Glue Degraders Undruggable Disease Targets Enabled by GlueXplorer Platform</p> <p><b>Speaker:</b> Hao Dou, Degron Therapeutics, Director</p>	<p><b>Clinical Indication Development – CNS</b> 15:00-15:20   Presentation: Drug Development Efforts Targeting Depression and Alzheimer's Disease</p> <p><b>Speaker:</b> Yelin Chen, Chinese Academy of Sciences, Principal investigator, Interdisciplinary Research Center on Biology and Chemistry</p> <p>15:20-15:40   Presentation: Innovative Breakthroughs in CNS Drug Development</p> <p><b>Speaker:</b> Qi Zhong, Pfizer China R&amp;D Center, Associate Director, Clinical Development</p> <p>15:40-16:20   Panel Discussion: CNS Drug Development</p> <p><b>Panelists:</b> Chao Zhang, NeuShen Therapeutics, COO Qi Zhong, Pfizer China R&amp;D Center, Associate Director, Clinical Development Li Yan, Ice Bioscience, Chairman Yishan Sun, Ignis Therapeutics, Vice President of Biology</p> <p><b>CMC &amp; Quality Control</b> 16:20-17:20   Executive Panel Discussion: Innovative Breakthroughs in Small-Molecule Drug Development</p> <p><b>Panelists:</b> Jingrong Li, GenFleet Therapeutics, CTO Wenge Zhong, Qilu Regor Therapeutics, CTO</p> <p>17:20-18:00   Panel Discussion: Further Optimization of CMC and Quality Systems in Mature Platforms</p> <p><b>Panelists:</b> Shun Xiao, Ascantage Pharma, Senior Director, Analytics &amp; Quality Control Kunlin Wang, Allorion Therapeutics, Senior Scientist, CMC JinYue Tu, Suzhou Genhouse Bio Co., Ltd., CMC Director</p>	<p><b>Back to Contents</b></p> <p>20</p>

# BIOCHINA 2026 Oligonucleotide Drug Innovative Development Forum

# BIOCHINA 2026 Peptide Drugs Innovative Development Forum

# BIOCHINA 2026 Nucleic Acid Drug Innovative Development Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	<b>Opening Panel Discussion</b> 10:00-11:00   Panel Discussion: Innovative Collaborative Development of Oligonucleotide Drugs <b>Moderator:</b> Bin Shi, BridGene Biosciences, Partner <b>Panelists:</b> Xuefeng Zhang, ChainGen Bio, Co-Founder & COO Honghui Pan, Sirnaomics, CEO Xiaoye Su, CSPC Pharmaceutical, President, Research Institute Dr. Qunsheng Ji, Sirus Therapeutics, CEO	<b>Executive Panel Discussion</b> 09:00-09:20   Presentation: Global CLP-1 Landscape Analysis in Obesity <b>Speaker:</b> Jie Dai, PharmaCube, Senior Researcher 09:20-10:00   Panel Discussion: Innovation in Next-Generation Peptide Drugs <b>Panelists:</b> WenXin Song, Shanghai Minwei Biotechnology Co., LTD, Deputy general manager Xiao Zhang, Syneron Bio, CEO Bing Wang, Micot Pharmaceutical, CEO <b>Oral Cyclic Peptides</b> 10:00-10:20   Presentation: Oral Cyclic Peptide: A New Modality? <b>Speaker:</b> Chenguang Yuan, Sungener Biologics, Co-Founder & CSO 10:20-10:40   Presentation: Structural Modification and Screening Methods <b>Innovative Target Development Case Sharing</b> 10:40-11:00   Presentation: Rapaglues—A Bridge between Macrocyclic Peptides and Molecular Glues for Interrogating Hard to Drug Targets <b>Speaker:</b> Rick Ewing, Rapafusyn, VP Head of Chemistry	<b>mRNA Cancer Vaccines</b> 09:00-09:40   Panel Discussion: Future Development of mRNA Cancer Vaccines <b>Moderator:</b> Chenyang Wu, Pivotal BioVenture Partners, Investment Director <b>Panelists:</b> Rongkuan Hu, Starna Therapeutics, Founder & CEO Changyun Xiong, Junjian Biotechnology, CEO Ajin Hui, MD, PhD, EnCureGen Pharma, Founder, Chair & CEO 09:40-10:00   Presentation: triVac Universal Modification Platform Enabling Cancer Vaccine Development <b>Speaker:</b> Dr. Shiyu Li, Tricision Biotherapeutics, Inc, Co-Founder & CEO 10:00-10:20   Presentation: Clinical Exploration and Key Breakthroughs in mRNA Therapeutic Cancer Vaccines <b>Speaker:</b> Xiangrong Song, Ph.D., WestGene Biopharma, CEO & Scientific Co-Founder 10:20-10:40   Presentation: Advancing mRNA Vaccines and Therapies: Collaboration, Science, and Impact <b>Speaker:</b> Roberta Duncan 10:40-11:00   Presentation: TBC <b>Speaker:</b> Shan Cen, RinuaGene Biotechnology, CSO
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<b>Oligonucleotide Drug Clinical Development Case Sharing</b> <b>Planner:</b> Dong You, Executive VP of Clinical R&D, ViaZen 12:00-12:20   Presentation: Analysis of Clinical Development Strategies for siRNA Drugs and Overview of Clinical Data <b>Speaker:</b> Dr. Dong You, Visirna Biotech, EVP 12:20-12:40   Presentation: Clinical Development and Progress of siRNA Drugs in Cardiovascular/Metabolic Diseases <b>Speaker:</b> Libang Qi, Visirna Therapeutics, MD, Medical 12:40-13:00   Presentation: Clinical Development and Progress of siRNA Drugs in Non-Cardiovascular/Metabolic Diseases <b>Speaker:</b> Jing Hao, Visirna Therapeutics, MD, Medical <b>Clinical Indication Exploration of Oligonucleotide Drugs</b> 13:00-13:20   Presentation: Anti-Tumor Oligonucleotide Drug HC016 <b>Speaker:</b> Jun Bai, Haichang Biotech, Head of Small Nucleic Acid Department 13:20-13:40   Presentation: IgA Nephropathy 13:40-14:00   Presentation: Functional Cure Indication for Clinical Hepatitis B <b>Speaker:</b> Zhongnan Xu, Siranbio, VP	<b>Phase III Clinical Project Development</b> 12:00-12:20   Presentation: Diabetes Project Development <b>Speaker:</b> Wei Chen, Gan & Lee Pharmaceuticals, Chairman, President & CEO 12:20-12:40   Presentation: Metabolic Diseases <b>Speaker:</b> Lin Zhang, Shanghai Benemae Pharmaceutical Corporation, Medical department Head <b>GLP-1 Development Case Sharing</b> 13:00-13:20   Presentation: GLP-1 Clinical Development Strategies and Value Redefinition <b>Speaker:</b> Jiaowei Lu, Innovent, Clinical Development Sr. Director 13:20-13:40   Presentation: Development of Anti-obesity Peptide Drugs <b>Speaker:</b> Nan Zheng, Shenzhen Bay Laboratory, Researcher at the Conversion Innovation Center 13:40-14:00   Presentation: Development Strategies for Ultra-Long-Acting Weight-Loss Drugs <b>Speaker:</b> Yuanyuan Zhang, Peptide Biomedical, Co-Founder, SVP & Head of R&D	<b>Potential mRNA Development Based on Cell-Targeting Technologies</b> 12:00-12:20   Presentation: Development and Application Progress of Base Editing Technologies for Targeted mRNA <b>Speaker:</b> Rong Xin, Shixi Biologics, CEO 12:20-12:40   Presentation: Fat-Targeted Development Research <b>Speaker:</b> Suhyi Huang, Axter Therapeutics, VP 12:40-13:00   Presentation: Research on mRNA Delivery Systems and Applications <b>Speaker:</b> Jianbin Tang, Zhejiang University, Professor, School of Chemical Engineering and Biotechnology 13:00-13:20   Presentation: Lipid Carrier Design and Its Exploration in RNA Drug Development <b>Speaker:</b> Xueqing Zhang, Rongcan Biotech, CSO & Professor, School of Pharmaceutical Sciences, Shanghai Jiao Tong University
14:00-15:00	Networking & Events	Networking & Events	<b>Circular mRNA Technology Innovation</b> 13:20-13:40   Presentation: Circular RNA Drug Development and Latest Progress <b>Speaker:</b> Dr. Chenxiang Tang, CirCode Biomed, CEO 13:40-14:00   Presentation: Applications of Circular RNA in Oncology, Autoimmune Diseases, and Regenerative Medicine <b>Speaker:</b> Chijian Zuo, Suzhou CureMed Biopharma Technology Co., Ltd, Vice President 14:00-14:20   Presentation: Process Optimization of Circular RNA <b>Speaker:</b> Jingyuan Wu, CirCode, Director, CMC 14:20-14:40   Presentation: Overcoming CMC Technical Challenges <b>Speaker:</b> Shaoyun Qi, Abogen Biosciences, Head of Circular RNA Platform
15:00-18:00	<b>Oligonucleotide Drug Technology Development &amp; CMC Strategies</b> 15:00-15:20   Presentation: Progress in Diabetes and Ophthalmology Small Nucleic Acid Drug Development at Anlong Bio <b>Speaker:</b> Chunlin Zhao, Ph.D, AnlongBio/AnlongMed, Founder 15:20-16:00   Panel Discussion: Oligonucleotide Drug Development and Industrialization Challenges <b>Moderator:</b> Peter Zhang, Suzhou GenePharma Co., Ltd, Chairman & CSO <b>Panelists:</b> Yi Huang, Chengdu Goworld Pharmaceutical Co., Ltd., General Manager of the Innovative Drug Division Dr. Jingqiao Wan, Leaderma Therapeutics Ltd., Chairman & CEO Sheng Zhou, Lisure Science, Deputy General Manager Huifang Dong, Porton Pharma Solutions, Head of Large Molecule Drug R&D and Manufacturing Center Chengjiang Zhao, Youjia Bio, Director of Youjia Institute for RNAi therapeutics <b>Non-Liver Targeted Delivery Research</b> 16:00-16:20   Presentation: Expanding RNAi Therapies Beyond the Liver – Unlocking the Full Potential of RNAi Delivery <b>Speaker:</b> Jiehua Zhou, Leaderma Therapeutics, Ltd., Co-Founder & CSO 16:20-16:40   Presentation: Development and Progress of Small Interfering Nucleic Acid Nanoparticles for Local Fat Reduction <b>Speaker:</b> Weiwei Tian, Sirnaomics, General Manager 16:40-17:00   Presentation: TBC <b>Speaker:</b> Yun Wu, Yunho Biotech, Co-Founder & Chief Scientific Officer (CSO) 17:00-17:20   Presentation: Small Nucleic Acid Drugs Will Impact the Fat Reduction and Muscle Building Market <b>Speaker:</b> Lorenzo Xie, Ph.D., Ractigen Therapeutics, CSO 17:20-17:40   Research Progress on Non-Liver Targeted Obesity Small Nucleic Acid Drugs <b>Speaker:</b> Yanhui Wang, Innovent Biologics, Associate Director, Nucleic Acid Therapeutics & Head of siRNA Drug Discovery 17:40-18:00   Q&A / Discussion	<b>Case Studies in GLP-1 Drug Development</b> 15:00-16:00   Panel Discussion: Multi-Indication Exploration – From AD Failure to MASH Breakthrough <b>Moderator:</b> Xiaogang Hui, InnoGen Pharmaceutical, Medical Director <b>Panelists:</b> Dr. Meng Liu, Hastein Biopharmaceutical, Vice President, Head of Medical Tongying Wang, Hangzhou Jiuyuan Gene Engineering Co., Ltd., Technical Director Shanghai Medicilon Inc. Meng Qiao, Pfizer, Director Xiancheng Zeng, Medicilon, VP of Preclinical Research <b>Planner:</b> Dr. Zifei Yuan, Gan & Lee Pharmaceuticals, VP & CTO <b>Peptide Synthesis Process &amp; Production Key Points</b> 16:00-16:20   Presentation: CMC Development Strategies and Core Considerations for Biocomposite Formulations <b>Speaker:</b> Dr. Zifei Yuan, Gan & Lee Pharmaceuticals, VP & CTO 16:20-16:40   Presentation: Process Optimization and Key Technological Breakthroughs for Industrialization <b>Speaker:</b> Fengyun Yang, Gan & Lee Pharmaceuticals, Director, Formulation Development 16:40-17:00   Presentation: Key Points in Peptide Drug Production Optimization <b>Speaker:</b> Dr. Wancai Xing, Gan & Lee Pharmaceuticals, Director of the R&D Analysis Department <b>Peptide Commercial Production Planning</b> 17:00-17:20   Presentation: Full Lifecycle CMC Development Strategies and Risk Management for Peptide Drugs <b>Speaker:</b> Vincent Qu, Shenzhen ScienCare Pharmaceutical Co., Ltd., CTO 17:20-18:00   Panel Discussion: Overcoming Challenges in Large-Scale Peptide Production and Process Scale-Up <b>Panelists:</b> Dr. John Fan, Micot Pharmaceutical Technology Co., VP of CMC Dongdong Huo, Sepax Technologies, Director of Applications Peng Zhai, Peptide Biomedical, Co-Founder & SVP	<b>RNA Delivery &amp; Future Applications</b> 14:40-15:00   Presentation: TBC <b>Speaker:</b> Dr. Sean Semple, Acuitas Therapeutics Inc., VP, Preclinical 15:00-15:40   Panel Discussion: Breakthroughs in Nucleic Acid Drug CMC Processes and Future Delivery Innovations <b>Panelist:</b> Dr. Yun Yang, Shanghai CirCode Biomed, Co-Founder, Chairman & CTO Youru Wang, Ningbo Junjian Biotechnology Co., Ltd., CSO Xueqing Zhang, Rongcan Biotech, CSO & Professor, School of Pharmaceutical Sciences, Shanghai Jiao Tong University

Back to Contents

Date	March 12th	March 13th	March 14th
09:00-11:00		<p><b>Global ADC Development and Collaboration</b> 09:00-10:00   Panel Discussion: Global Strategy and Collaboration in ADC Drug Development <b>Moderator:</b> Hu Li, Ph.D., ERVC, Venture Partner <b>Panelists:</b> Ziping Wei, Bridge Biotherapeutics (Hangzhou) Co., Ltd., Co-Founder, Chairman, &amp; CEO Ziye Sui, Lepu Biopharma Co., Ltd., CEO Yongxin Zhao, Hangzhou DAC Biotechnology Co., Ltd., Founder &amp; CEO Jingcai Li, WuXi XDC, CEO Jiadiang Cai, MediLink Therapeutics, Co-Founder &amp; Co-CEO &amp; CSO</p> <p><b>10:00-11:00   XDC Drug R&amp;D – Ruizhii Pharma Special Session</b> 10:00-10:30 Presentation: XDC – Chemistry Focus <b>Speaker:</b> Yong Sui, Chempartner Pharmatech, Associate Director, Chemistry R&amp;D 10:30-11:00 Presentation: XDC – Biology Focus <b>Speaker:</b> Guihe Liang, Chempartner Pharmatech, Director, XDC &amp; Biologics R&amp;D</p>	<p><b>XDC: From Preclinical to Clinical Focus</b> 09:00-10:00   Panel Discussion: From Preclinical to Clinical Stages: Developability Assessment and Clinical Strategy Optimization for XDCs <b>Panelists:</b> Xuebin Liu, Inxmed, Senior Vice President (SVP) Dr. Zhaorong Chen, Doma Biopharmaceutical (Suzhou) Co., Ltd., CMO Mo Xu, Yahong Meditech, Head of Clinical Development &amp; SVP Xingquan Ma, Chempartner Pharmatech, Co-President &amp; Head of Chemistry BU Rang Gao, M.D., Xiling Lab, CMO</p> <p>10:00-10:20   Presentation: Bridging the Gap: Leveraging AI for Precision Degrader &amp; DAC Design on "Plug-and-Play" Scaffolds to Ensure Rapid Execution <b>Speaker:</b> Masahiko Hayakawa, Ubiquarian Therapeutics, Ph.D., MBA / CSO</p> <p>10:20-10:40   Presentation: Challenges Across the Full Process from Preclinical Research to Clinical Trials 10:40-11:00   Presentation: Combination Therapy Strategies for XDC</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>AI-Enabled Drug Discovery and Development</b> 12:00-13:00   Panel Discussion: Technological Breakthroughs and Practices from Target Discovery to Clinical Translation <b>Panelists:</b> Dr. Lipeng Lai, XtalPi, Co-Founder &amp; CIO Yun Zhu, Yunhu Biotechnology, CEO Xuan Xian, GeneScience Pharmaceutical, Director, AI Drug Discovery Institute Dr. Di Hong, Nona Biosciences, CEO Jian Zhang, Nutshell Therapeutics, Founder Lianyi Han, Ph.D., Hengrui, Head of AIDD</p> <p><b>13:00-14:00   Tianwu Technology Special Session</b> <b>AI Applications in Next-Generation Innovative Protein Drug Development</b> 13:00-13:20   Presentation: AI-Driven Innovation in Biopharmaceutical R&amp;D <b>Moderator:</b> Xiaoyan Wang, 3E Bioventures Capital, Partner <b>Speaker:</b> Song Li, Matwings Technology, Head of AI Biopharmaceutical R&amp;D 13:20-14:00   Panel Discussion: AI Breakthroughs: R&amp;D and Application of Next-Generation Innovative Protein Drugs <b>Moderator:</b> Xiaoyan Wang, 3E Bioventures Capital, Partner <b>Panelists:</b> Liang Hong, Shanghai Jiao Tong University, Distinguished Professor &amp; Chief Scientist, Matwings Technology Han Dai, Viva Biotech Holdings, Chief Innovation Officer (CINO) Zhi Chen, OTR Therapeutics, Founder &amp; CEO</p>	<p><b>Latest ADC R&amp;D and Clinical Progress</b> 12:00-12:20   Presentation: Progress in Bispecific and Dual-Target ADC Research <b>Speaker:</b> Siyi Hu, Phrontline Biopharma, Deputy General Manager 12:20-12:40   Presentation: Bispecific Toxin ADC Development <b>Speaker:</b> Jiawei Lu, WuXi XDC, Head of Conjugate R&amp;D 12:40-13:00   Presentation: Clinical Validation of Next-Generation ADC Platform Technologies <b>Speaker:</b> Dr. Qing Zhou, Escugen Biotechnology, Founder &amp; CEO 13:00-13:20   Presentation: Clinical Insights of Bispecific ADCs <b>Speaker:</b> Dr. Zhaorong Chen, Doma Biopharmaceutical (Suzhou) Co., Ltd., CMO 13:20-13:40   Presentation: Early Clinical Development: Successes, Failures, and Lessons Learned <b>Speaker:</b> Rang Gao, Innovative Drug Company, CEO 13:40-14:00   Q&amp;A / Discussion</p>	<p><b>PDC Innovation and Clinical Development</b> 12:00-12:20   Presentation: Bi-XDC – Innovative Oncology Pipeline Targeting Unmet Needs and Clinical Progress <b>Speaker:</b> Ji Yang, COHERENT BIOPHARMA (SUZHOU) Co., Ltd., Clinical Operations Director 12:20-12:40   Presentation: Synergistic Effects of Dual-Target PDC Design <b>Speaker:</b> Jun Shao, Coherent Biopharma, CTO 12:40-13:00   Presentation: Peptide-Drug Conjugate (PDC) Delivery Strategies <b>Speaker:</b> Xiaoyu Zang, N1Life, CEO</p> <p><b>Conjugation Technology Focus</b> 13:00-13:20   Presentation: Application of Novel ADC Technologies and Clinical Translation <b>Speaker:</b> Wei Lian, MediLink Therapeutics (Suzhou) Co., Ltd., VP of Translational Medicine 13:20-13:40   Presentation: Addressing ADC Resistance: Next-Generation ADC Platforms and Pipelines 13:40-14:00   Presentation: Oligonucleotide Conjugates (AOC/ODC) 14:00-14:20   Presentation: Protein-Conjugated Drugs (PLC) 14:20-14:40   Presentation: Radiolabeled Conjugates (RDC) 14:40-15:00   Presentation: Protein-Conjugated Drugs (PLC)</p>
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	<p><b>New Paradigms in Antibody Discovery and Development Driven by AI and Automation</b> 15:00-16:00   Mega Technology Special Session <b>Moderator:</b> Fuming Zhao, MegaRobo Technologies, Director of Product Marketing 15:00-15:20   Presentation: Antibody R&amp;D Accelerator — The Synergistic Revolution of AI and Automation <b>Speaker:</b> Shiqiang Liu, MegaRobo Technologies, Senior Product Manager 15:20-16:00   Panel Discussion: In the AI+ Era, How Can Companies Restructure Antibody R&amp;D Efficiency and Barriers to Leapfrog Ahead? <b>Moderator:</b> Yan Zhang, MegaRobo Technologies, Co-Founder &amp; SVP <b>Panelists:</b> Yuguang Wang, Tousun Synbio, Founder &amp; CEO &amp; Associate Professor, Shanghai Jiao Tong University Xin Guo, Shanghai Institute of Science and Intelligence, Chief Researcher Ruilian Hu, Chempartner Pharmatech, Chairman &amp; CEO</p> <p><b>Innovative Practices in Multi-Modality Drug Development and Process Manufacturing</b> 16:00-16:20   Presentation: From Generative AI to the Clinic: AI-Driven End-to-End Drug Discovery and Development <b>Speaker:</b> Jie Wang, InSilico Medicine Cayman TopCo, VP, Business 16:20-16:40   Presentation: Application Cases of AI in Peptide and Nucleic Acid Drug Development <b>Speaker:</b> Dr. Lipeng Lai, XtalPi, Co-Founder &amp; CIO 16:40-17:00   Presentation: TBC <b>Speaker:</b> Lianyi Han, Ph.D., Hengrui, Head of AIDD 17:00-17:20   Presentation: AI-Empowered Process Manufacturing: A Case Study from GenSci Pharmaceutical <b>Speaker:</b> Xuan Xian, GeneScience Pharmaceutical, Director, AI Drug Discovery Institute 17:20-17:40   Presentation: AI-Enabled Biopharmaceutical Fermentation Processes <b>Speaker:</b> Dr. Khaled Baraka, Thoth BioSimulations, CEO &amp; Chief Scientist 17:40-18:00   Presentation: AI-Driven Drug Production Quality and Compliance Management</p>	<p><b>Differentiated Targets and Molecular Design</b> 15:00-16:00   Panel Discussion: Differentiated Design Driving Bispecific/Multispecific ADC Breakthroughs and Innovative Approaches in Linker-Payload Development <b>Moderator:</b> Yinghui Yu, Johnson &amp; Johnson, Senior Director, Global BD <b>Panelists:</b> Lili Shi, GeneQuantum Healthcare, Vice President of R&amp;D Yuhong Zhou, BlissBio, CSO Xiu Hui, CSPC Pharmaceutical, President, Research Institute Nianhe Han, Ximma Biomedical, CSO Yangsheng Qiu, Huahai Tianheng, SVP</p> <p><b>From Oncology to Autoimmunity: ADC Clinical Pathology and Combination Therapy</b> 16:00-16:20   Presentation: ADC Drug Development Progress in Lung Cancer <b>Speaker:</b> Anwen Xiong, Shanghai East Hospital, Associate Chief Physician, Associate Professor 16:20-16:40   Presentation: Computational pathology to guide use of ADCs <b>Speaker:</b> Dr. Hadassah Sade, AstraZeneca Computational Pathology, Managing Director 16:40-17:00   Presentation: ADC Development and Clinical Progress in Autoimmune Diseases <b>Speaker:</b> Dr. Li Xi, Duality Biotherapeutics, Executive Director, R&amp;D 17:00-17:20   Presentation: TBC <b>Speaker:</b> Zhenwei Miao, IMBIORAY (Hangzhou) Biomedicine Co., Ltd, Chairman &amp; CEO 17:20-17:40   Presentation: Combination Therapy of ADC and Bispecific Antibodies <b>Speaker:</b> Wei Li, Shanghai Dongfang Hospital, Associate Chief Physician 17:40-18:00   Q&amp;A / Discussion</p>	<p><b>Back to Contents</b></p> <p><b>22</b></p>

# BIOCHINA 2026 Antibody Drug Innovative Development Forum

# BIOCHINA 2026 Regenerative Medicine & Tissue Repair Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	<p>09:00-10:00   Panel Discussion: Focused Segment Analysis – Bispecific and Multispecific Innovative Drug Pipeline and Collaboration Strategies from a BD Perspective</p> <p><b>Moderator:</b> Scott Liu, Ph.D., HanchorBio Inc., Founder, Chairman &amp; CEO</p> <p><b>Panelists:</b> ZhenHao Zhou, Chimagen Biosciences, Founder &amp; CEO Dr. Lei Fang, Aikelan Biotech, Co-Founder, Chairman &amp; CEO Dr. Chao Tu, Biomissile Pharmaceuticals, Co-Founder, President &amp; CEO Dr. Pengfei Zhou, WUHAN YZY BIOPHARMA CO., LTD., Founder, Chairman &amp; CEO</p> <p>10:00-11:00   ZhuHai Jinwan Special Session</p>	<p><b>Progenitor Cell Regenerative Therapy</b></p> <p><b>Planner:</b> Dr. Ting Zhang, Regend Therapeutics, Founder &amp; CEO</p> <p>09:00-09:20   Presentation: Autologous Renal Progenitor Cell-Based Kidney Stem Cell Product</p> <p><b>Speaker:</b> Yu Ma, Regend Therapeutics, VP</p> <p>09:20-09:40   Presentation: Research on Tissue-Specific Adult Stem/Progenitor Cells in Chronic Diseases and Organ Repair</p> <p><b>Speaker:</b> Wei Rao, Zhejiang University School of Medicine, Researcher in Severe Liver Diseases</p> <p><b>Speaker:</b> Zhihu Weng, Saliwei Biotech, Deputy General Manager</p> <p>10:00-10:20   Presentation: TBC</p> <p><b>Speaker:</b> Xia Wang, Tsinghua University, Special Researcher</p> <p>10:20-11:00   Panel Discussion: TBC</p> <p><b>Panelists:</b> Dr. Ting Zhang, Regend Therapeutics, Founder &amp; CEO Wei Rao, Zhejiang University School of Medicine, Researcher Zhihu Weng, Saliwei Biotech, Deputy General Manager</p> <p>Xia Wang, Tsinghua University, Special Researcher</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p>12:00-13:00   Panel Discussion: Strategic Collaboration Perspective – Core Challenges and Solutions in Global Capacity Building</p> <p><b>Moderator:</b> Youchen Chen, HBM Holdings Limited, CFO</p> <p><b>Panelists:</b> Dr. Haibin Wang, BioRay Pharmaceutical Co., Ltd., CEO Dr. Wenzhi Tian, ImmuneOnco Biopharma, Founder, Chairman &amp; CEO</p> <p><b>Complex Molecular Innovative Development</b></p> <p>13:00-13:20   Presentation: Logic-Gated Technologies and Intelligent Antibody Therapeutics</p> <p><b>Speaker:</b> Zhiqiang Tian, Chinese Academy of Engineering, Académicien</p> <p>13:20-13:40   Presentation: IL15v-NKCE: A cutting-edge NK cell engager platform for cancer treatment</p> <p><b>Speaker:</b> Xuan Wu, EpimAb Biotherapeutics, Inc., Senior Director of Biotechnology Department</p> <p>13:40-14:00   Presentation: Development of mRNA-Encoded Bispecific T-Cell Engagers (TCEs)</p>	<p><b>Antibody Drug Development and Clinical Research Based on Different Targets</b></p> <p><b>Planner:</b> Yanfeng Zhang, AlaMab Therapeutics Inc., Co-Founder &amp; CEO</p> <p>12:00-12:20   Presentation: Claudin 6/9 ADC – Integrating a Unique Innovative Linker Platform with Target Biology</p> <p><b>Speaker:</b> Yanfeng Zhang, AlaMab Therapeutics Inc., Co-Founder &amp; CEO</p> <p>12:20-12:40   Presentation: Clinical Progress</p> <p><b>Speaker:</b> Xuguang Yang, CSPC Pharmaceutical Group Co., Ltd., Senior Medical Director</p> <p>12:40-13:00   Presentation: Drug Development and Clinical Research of Innovative Targets</p> <p><b>Speaker:</b> Sheng Tu, Hope Medicine Inc., President</p> <p><b>Antibody Drug Development and Clinical Research Across Different Indications</b></p> <p>13:00-13:20   Presentation: Next-Generation Anti-BDCA2 mAb with Bifunctional Activity: Simultaneously Inhibiting both IFN<math>\alpha</math> and B cells</p> <p><b>Speaker:</b> Haomin Huang, 3sbio Inc., Vice president of R&amp;D</p> <p>13:20-13:40   Presentation: TBC</p> <p><b>Speaker:</b> Yifan Zhan, Shanghai Huatao Biopharmaceutical Co., CSO, VP of Drug Discovery</p> <p>13:40-14:00   Presentation: TBC</p> <p><b>Speaker:</b> Wanmei Wang, Trinomab Biotechnology, CMO&amp;高级副总裁</p>	<p>12:00-13:00   <b>Stem Cells and Regenerative Medicine</b></p> <p>12:00-12:20   Presentation: Breakthroughs in iPSC-Based Regenerative Transplantation</p> <p><b>Speaker:</b> Maofa Zheng, Celregen Biotechnology, President</p> <p>12:20-12:40   Presentation: A Novel Hybrid Regenerative Medicine Product: Combining iPSC-Derived Cardiovascular Cells and Biomaterials</p> <p><b>Speaker:</b> Kenji Kakita, iHeart Japan, CEO</p> <p>12:40-13:00   Presentation: Global First-In-Class: A Novel Multicomponent Protein Therapeutic for Reversing Neurodegenerative Diseases and Brain Injury — Cell-Free, Non-Exosomal, Industrially Standardized, Scalable, and Safe</p> <p><b>Speaker:</b> Chen Chen, Darwincell Biotech Ltd., CBO</p> <p>13:00-14:00   <b>Regenerative Medicine and Tissue Repair</b></p> <p>13:00-13:20   Presentation: TBC</p> <p>13:20-13:40   Presentation: Exploring the Clinical Application Prospects of GHRH Analog Peptide Drugs</p> <p><b>Speaker:</b> Hong Yu, Zhejiang University, Professor &amp; Founder, Sinoep Allsino Bio Pharmaceutical</p> <p>13:40-14:00   Presentation: Latest Clinical Progress in Fibroblast-Based Cell Therapy for Degenerative Disc Disease (Tentative)</p> <p><b>Speaker:</b> Ming Fan, Chuiyuan Medicine, Founder &amp; CEO</p>
14:00-15:00	Networking & Events	Networking & Events	<p>13:00-14:00   <b>Organoids and Tissue Engineering</b></p> <p>14:00-14:20   Presentation: Development and Application of Allogeneic Off-the-Shelf Universal Tumor-Infiltrating Lymphocytes</p> <p><b>Speaker:</b> Hua Liu, Xinghua Bio, Founder &amp; CSO</p> <p>14:20-14:40   Presentation: Neural Regeneration and Spinal Cord Repair</p> <p>14:40-15:00   Presentation: Tissue Regeneration and Trans-Germ Layer Differentiation</p> <p>15:00-16:00   Panel Discussion: How Can Regenerative Medicine Technologies Be Translated into Scalable Repair Solutions?</p>
15:00-18:00	<p><b>Bispecific Antibody Latest R&amp;D and Clinical Progress</b></p> <p>15:00-15:20   Presentation: Progress and Clinical Development of PD1/VEGF Bispecific Antibodies</p> <p><b>Speaker:</b> Qiyiing Lu, INSTIL BIO, CMO</p> <p>15:20-15:40   Presentation: Bispecific Antibody Development, Design, and Validation in Inflammation</p> <p><b>Speaker:</b> Tao Chen, Qyuns Therapeutics, Head of Drug Development</p> <p>15:40-16:00   Presentation: Preclinical Development of T-Cell Engaging Bispecific Antibodies (TCEs)</p> <p><b>Speaker:</b> Bing Hou, Antengene, Executive Director of Early Drug Development</p> <p><b>Trispecific / Multispecific Antibody Latest R&amp;D and Clinical Progress</b></p> <p>16:00-16:20   Presentation: Latest Clinical Progress of Trispecific TCEs</p> <p><b>Speaker:</b> Yingfeng Huang, Cytocares, CEO</p> <p>16:20-16:40   Presentation: Trispecific Logic-Gated TCE Development</p> <p><b>Speaker:</b> Zuoxiang Xiao, Shimai Pharmaceutical, Chairman &amp; Founder</p> <p>16:40-17:00   Next-Generation Trispecific Antibody Development for Solid Tumor Therapy</p> <p><b>Speaker:</b> Xianghai Cai, Novatim Immuno Therapeutics (Zhejiang) Co., Ltd., VP</p> <p>17:20-18:00   Panel Discussion: R&amp;D Innovation Perspective — Breaking Through in Antibody Drug Development: From Target Discovery to Full-Spectrum Molecular Design Upgrade</p> <p><b>Moderator:</b> Hong Ling, Leads Biolabs, CSO</p> <p><b>Panelists:</b> Junming Yie, Shenzhen Salubris Pharmaceuticals Co., Ltd., CSO Dr. Bo Chen, China Resources Pharmaceutical Group Limited, CSO Dong Li, RemeGen Co., Ltd., General Manager, Shanghai R&amp;D Center Hua Ying, Qilu Institute of Innovative Pharmaceutical Research, Vice president, Head of Biologics Discovery Jinming Gu, Sunshine Guojian Pharmaceutical, Vice President, R&amp;D Kedan Lin, Biosion, Inc., Chief Development Officer (CDO)</p>	<p>15:00-15:20   Presentation: Global Trends in Bispecific/Multispecific Innovative Drugs</p> <p><b>Speaker:</b> Shuona Yuan, PharmaCube, Senior Researcher</p> <p>15:20-16:20   Panel Discussion: Clinical Translation Perspective – End-to-End Strategies for Antibody Drug Development from Clinical Trials to Market Access</p> <p><b>Moderator:</b> Zhili Wu, ImmuneOnco Biopharmaceuticals, CMO</p> <p><b>Panelists:</b> Xinghua Hou, Huiyu Pharmaceuticals, CMO Jinjin Liang, Mabworks Biotechnology, CMO Wang Cong, MEDx, SVP of Research</p> <p><b>Antibody Combination Therapies</b></p> <p>16:20-16:40   Presentation: Dose Optimization Across the Full Drug Lifecycle</p> <p><b>Speaker:</b> Naihan Chen, Pfizer, VP of Clinical Pharmacology</p> <p>16:40-17:00   Presentation: Dual Immunotherapy Combinations</p> <p>17:00-17:20   Presentation: Bispecific Antibody Combinations</p> <p>17:20-17:40   Q&amp;A / Discussion</p>	<p><b>Back to Contents</b></p> <p><b>23</b></p>

# BIOCHINA2026 In Vivo CAR-T Innovation Forum

# BIOCHINA 2026 Stem Cell Drug Innovative Development Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	<p>Exhibition Hall Closed During Opening Ceremony</p> <p>10:00-11:00   Opening Panel Discussion: Commercialization Decision-Making Driven by Policy, Capital, and Market  <b>Moderator:</b> Yuanyuan Sun, Industrial Securities, Chief Analyst  <b>Panelist:</b> Xingrong Chen, Fosun Kairos, CEO          Yu Xiang, BRL Medicine Inc., CEO</p>	<p><b>CMC &amp; Delivery</b>          09:00-10:00   Panel Discussion: Non-Clinical and CMC Considerations from IND Filing  <b>Moderator:</b> Eric Xu, TCRCure, VP of MFG  <b>Panelists:</b> Min Wang, PersonGen, VP          Qinbin Wu, OBIO Technology, Deputy General Manager &amp; CQO</p> <p><b>In Vivo CAR-T Delivery</b>          10:00-10:20   Presentation: In Vivo CAR-T Delivery Based on mRNA-LNP Platform: Technology and Clinical Applications  <b>Speaker:</b> Xiangrong Song, Ph.D., WestGene Biopharma, CEO &amp; Scientific Co-founder          10:20-10:40   Presentation: In vivo mRNA-encoded immune cell engagers  <b>Speaker:</b> Wei Xu, METIS Pharmaceuticals, CSO          10:40-11:00   Presentation: Targeted Delivery Strategies for mRNA CAR-X Therapy  <b>Speaker:</b> Liyan Feng, Rhegen Biotech, Director of R&amp;D</p>	<p><b>iPSC Development Session</b>          09:00-09:20   Presentation: Cell Therapy for Parkinson's Disease: Clinical Efficacy Validation and Global Progress of Next-Generation Therapies  <b>Speaker:</b> Binyan Lu, Regen Therapeutics, VP, Product Projects          09:20-09:40   Presentation: Development and Clinical Translation of Pluripotent Stem Cells in Heart Failure  <b>Speaker:</b> Yongsheng Xu, HELP Therapeutics, Co-Founder &amp; CTO          09:40-10:00   Presentation: Clinical Progress of iPSC-Derived Endothelial Progenitor Cell Injections for Ischemic Vascular Diseases  <b>Speaker:</b> Huiyuan Zhang, Allife Medical Science and Technology Co., Ltd., Senior Quality Director          10:00-10:20   Presentation: Clinical Development and International Strategy of Human iPSC-Derived Neural Progenitor Cell Injection  <b>Speaker:</b> Jing Fan, Hopstem Bioengineering Co.,Ltd, Founder &amp; CEO          10:20-10:40   Presentation: TBC  <b>Speaker:</b> Fangfang Zhu, HemaCell Biotechnology Inc., CEO          10:40-11:00   Presentation: TBC  <b>Speaker:</b> Xi Yan, Wiseheart MedVal, Vice President</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>Clinical Development</b>          12:00-13:00   Panel Discussion: Core Technology Routes and Clinical Strategies at the IIT Stage  <b>Panelists:</b> Zhuoxiao Cao, Simnova Biotech, CEO          Kaikai Shi, DeliNova Therapeutics, Founder &amp; CEO          Cheng Qian, Precision Biotech, Chairman &amp; CSO          Ting He, IMUNOPHARM Technology Co., Ltd., CEO</p> <p>13:00-13:20   Presentation: Future Directions and Research Trends of Cell Therapy from a Regulatory Perspective  <b>Speaker:</b> Jinghua Zhao, Fosun Kairos, CMO</p> <p>13:20-13:40   Presentation: In Vivo CAR-T Tumor Therapy and Latest Clinical Progress (Tentative)  <b>Speaker:</b> Cheng Qian, Precision Biotech, Chairman &amp; CSO</p> <p>13:40-14:00   Presentation: Anticipating and Managing Safety of In Vivo CAR-T</p>	<p><b>Process &amp; Quality</b>          12:00-12:20   Presentation: Selection of Vectors and Process Development for In Vivo Cell Therapy  <b>Speaker:</b> Min Wang, PersonGen, VP</p> <p>12:20-13:00   Panel Discussion: In Vivo CAR-T Manufacturing Process Challenges</p> <p>13:00-14:00   Zhuhai Jinwan Special session</p>	<p><b>12:00-14:00 Stem Cell Processes and Manufacturing Session</b>          12:00-12:20   Presentation: Development Strategies and Key Challenges of Pluripotent Stem Cell Product Processes  <b>Speaker:</b> Alex Wu, Unixell Biotech, CMC sVP</p> <p>12:20-12:40   Presentation: Establishment of Release Testing Systems for Stem Cell Therapy Products  <b>Speaker:</b> Zhihui Bai, Shanghai East Hospital, Deputy Director of GMP Laboratory &amp; Director of Quality Control Department</p> <p>12:40-13:00   Presentation: TBC</p> <p>13:00-14:00   Panel Discussion: Innovative Practices and Future Trends in Scalable Stem Cell Manufacturing  <b>Speaker:</b> Alex Wu, Unixell Biotech, CMC sVP</p>
14:00-15:00	Networking & Events	Networking & Events	<p><b>14:00-16:00 MSC Development Session</b>          14:00-14:20   Presentation: Technological and Clinical Breakthroughs of iPSC-Derived MSC Products  <b>Speaker:</b> Chengyou Dong, Nuwacell Biotech Co., Ltd., GM Assistant</p> <p>14:20-14:40   Presentation: Clinical Progress and New Global Development Pathways of Stem Cell Therapy for Acute Ischemic Stroke  <b>Speaker:</b> Yingchun Jiang, Wingor Biotechnology, VP, Technology</p> <p>14:40-15:00   Presentation: Latest Clinical Progress of MSC Therapy for Liver Cirrhosis  <b>Speaker:</b> Dr. Chen Zheng, Zhejiang Quansheng Biotechnology Co., Ltd., CTO</p> <p>15:00-15:20   Presentation: Clinical Exploration of MSC Therapy for Liver Failure  <b>Speaker:</b> Yi Tan, Qilu Cell Therapy, VP and R&amp;D Director</p> <p>15:20-16:00   Panel Discussion: Opportunities and Challenges in MSC Drug Development under the "Rule 818"  <b>Moderator:</b> Yi Tan, Qilu Cell Therapy, VP and R&amp;D Director</p> <p><b>Panelists:</b> Dr. Chen Zheng, Zhejiang Quansheng Biotechnology Co., Ltd., CTO          Jing Fan, Hopstem Bioengineering Co.,Ltd, Founder &amp; CEO          Yingchun Jiang, Wingor Biotechnology, VP, Technology</p>
15:00-18:00	<p><b>Innovative R&amp;D</b>          15:00-16:00   Panel Discussion: In Vivo CAR-T R&amp;D Progress and Development Prospects  <b>Panelists:</b> Lianjun Shen, GRACELL, SVP          Xiaowen He, Origincell Therapeutics, CSO          Xueliang Yu, Starna Therapeutics, Vice President          Bo Pei, Imviva Biotech, VP          Fengtao You, PersonGen BioTherapeutics(Suzhou) Co.,Ltd., Director          Innovative drug research Institute</p> <p><b>16:00-17:00   In Vivo CAR-T Development — LVV vs. LNP, Who Leads the Way</b>  <b>Planner:</b> Feifei Qi, Imunopharm Technology Co., Ltd., Co-Founder &amp; CTO</p> <p>16:00-16:05   Opening Briefing</p> <p>16:05-16:30   Presentation: Breakthroughs in Lentiviral Vector In Vivo CAR Technology  <b>Speaker:</b> Lin Yang, PersonGen BioTherapeutics (Suzhou) Ltd., Co-Founder &amp; Chairman &amp; CEO</p> <p>16:30-16:55   Presentation: In Vivo CAR-T Development Based on Circular RNA  <b>Speaker:</b> Dr. Yun Yang, CirCode Biomed Co-Founder, Chairman &amp; CTO</p> <p>16:55-17:00   Q&amp;A</p> <p>17:00-17:20   Presentation: Engineering In Vivo CAR-T: Key Challenges and Frontier Progress  <b>Speaker:</b> Nan Xu, Unicar-Therapy Bio-medicine, VP R&amp;D</p> <p>17:20-17:40   Presentation: In Vivo TCR-T R&amp;D  <b>Speaker:</b> Shi Zhong, Chief Scientist, PhD</p> <p>17:40-18:00   Presentation: TBC  <b>Speaker:</b> Tingting Wang, Lion TCR, COO &amp; CMO</p>	<p><b>BIOCHINA 2026 Stem Cell Drug Innovation Forum</b></p> <p><b>Stem Cell Industry Policy &amp; Translational Practice</b>          15:00-15:20   Opening Presentation  <b>Speaker:</b> Shaorong Gao, Tongji University, Distinguished Professor &amp; Dean, School of Life Sciences &amp; Technology &amp; Academician, Chinese Academy of Sciences</p> <p>15:20-15:40   Presentation: Lecheng Pilot Project</p> <p>15:40-16:00   Presentation: Regulatory Policies</p> <p>16:00-16:20   Presentation: Design of Phase III Clinical Trial of MSC for Knee Osteoarthritis (Tentative)  <b>Speaker:</b> Liang Xu, ElpasBio Holdings, VP, CMO &amp; CSO</p> <p>16:20-16:40   Presentation: Drug Development for Neurological Disorders  <b>Speaker:</b> Xiang Li, Xellsmart, CEO</p> <p>16:40-17:00   Presentation: Latest Progress in Gene-Modified MSC Therapy for Type 2 Diabetes</p> <p>17:00-18:00   Panel Discussion: Intersection of Technology, Clinical Practice, and Regulation — How to Facilitate the Industrialization of Stem Cell Innovative Drugs  <b>Panelists:</b> Yu Zhang, VCANBIO Cell &amp; Gene Engineering Corp., Ltd., Deputy General Manager          Lanlin Wu, UniXell Biotechnology, CEO</p>	<p><b>Back to Contents</b></p> <p><b>24</b></p>

## BIOCHINA2026 Exosome Innovative Development Forum

## BIOCHINA 2026 Cell Therapy Innovative Development Forum

## BIOCHINA2026 Gene Therapy Innovative Development Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	<p><b>Future Manufacturing</b> 09:00-09:40   Panel discussion: Choices and Considerations for Future Commercial Manufacturing <b>Moderator:</b> Ivan Lin, JW Therapeutics Ltd., Head of Manufacturing/Head of MSAT&amp;ATS <b>Panelists:</b> Wensi Wang, FOSUNKAIROS, SVP Binghe Tan, BRL Medicine Inc., Partner &amp; CTO Dr. Ruina Shi, Beijing Immunopharm Technology Co., Ltd., VP Pan Dai, 百思飞, Executive Director &amp; General Manager</p> <p>09:00-09:40   Presentation: Manufacturing of Allogeneic Human Immune Cells for Solid Tumor Immunotherapy <b>Speaker:</b> Andy Tan, Bioprocessing Technology Institute, A*STAR, Principal Scientist and Group Leader</p> <p><b>Innovation in Future Cell Therapy Manufacturing</b> <b>Planner:</b> Ivan Lin, JW Therapeutics Ltd., Head of Manufacturing/Head of MSAT&amp;ATS 10:00-10:20   Presentation: The Future of Bedside Cell Therapy Preparation under China's New Regulations: International Trends and Accessibility Breakthroughs <b>Speaker:</b> Ziqiu Guan, Milenyi Biotec, Head of Regulatory Affairs &amp; Clinical Expansion, China 10:20-10:40   Presentation: Fast CAR-T <b>Speaker:</b> Gracell Biotechnologies 10:40-11:00   Presentation: Considerations for CMC Global Expansion</p>	<p><b>Opening Panel discussion</b> 09:00-09:40   Panel discussion: Impact of New Biomedical Technology Regulations on the Gene Therapy Field <b>Panelists:</b> Wei Guo, China Pharmaceutical University, Professor, School of Excellence in Biopharmaceutical Engineering Kangjian Zhang, Yuansong Biotechnology, General Manager Dr. Binlei Liu, Binhui Biopharmaceutical, Founder, Chairman &amp; General Manager Yuanyuan Xu, Cure Genetics, CEO</p> <p><b>Technology and Clinical Innovation</b> 09:40-10:00   Presentation: Clinical Translation of Gene Therapies for Neural Regeneration <b>Speaker:</b> Yuchen Chen, NeuExcell Therapeutics, VP, R&amp;D 10:00-10:20   Presentation: Clinical Progress of In Situ Neuronal Regeneration Therapy for Parkinson's Disease <b>Speaker:</b> Dr. Jingmin Zhou, Genemagic Bio, Co-Founder &amp; CEO 10:20-10:40   Presentation: Innovative Telomere-Targeted Gene Therapy for Heart Failure: Clinical Study <b>Speaker:</b> Yangyang Liu, Shanghai Juvenis Therapeutics Biotechnology, Co-Founder &amp; Clinical Lead 10:40-11:00   Presentation: Clinical Data of Oncolytic Virus OH2 for Cold Tumors and Reversing Drug Resistance <b>Speaker:</b> Hanming Wang, Binhui Biopharmaceutical Co. Ltd., VP</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>Technological Innovation and Clinical Translation</b> <b>Planner:</b> Libo Zhao, Echo Biotech Co., Ltd., CTO &amp; Co-Founder 12:00-13:00   Panel discussion: Clinical Challenges and Breakthroughs in Exosome Therapy <b>Moderator:</b> Libo Zhao, Echo Biotech Co., Ltd, Co-Founder &amp; CTO <b>Panelists:</b> Haoran Xing, National Center for Nanoscience and Technology Yong Tao, Beijing Chaoyang Hospital, Capital Medical University, Dept. Ophthalmology Hang Hubert Yin, Tsinghua University, Beijing, Professor of Pharmaceutical Sciences Linzhao Cheng, USTC, Chair Professor &amp; Dean, School of Life Sciences and Medicine &amp; Tenured Professor, Johns Hopkins University</p> <p>13:00-13:20   Presentation: Exploratory Study of Engineered Extracellular Vesicle Therapy for Ophthalmic Diseases <b>Speaker:</b> Yong Tao, Beijing Chaoyang Hospital, Capital Medical University, Dept. Ophthalmology</p> <p>13:20-13:40   Presentation: Human Stem Cells and Engineered-Derived EVs <b>Speaker:</b> Linzhao Cheng, USTC, Chair Professor &amp; Dean, School of Life Sciences and Medicine &amp; Tenured Professor, Johns Hopkins University</p> <p>13:40-14:00   Presentation: Novel High-Efficiency Delivery Strategies <b>Speaker:</b> Hang Hubert Yin, Tsinghua University, Beijing, Professor of Pharmaceutical Sciences</p>	<p><b>Immunotherapy Drug Development</b> 12:00-12:20   Presentation: Synthetic NK Cells and Anti-Aging Immunotherapy <b>Speaker:</b> Zhigang Tian, Chinese Academy of Engineering, Academician 12:20-12:40   Presentation: Rapid Translation Strategies and Practices for Mature CAR-T Platforms <b>Speaker:</b> Bing Du, East China Normal University, Professor; BRL Medicine Inc., Co-Founder 12:40-13:00   Presentation: CAR-NK Therapy for Relapsed/Refractory SLE <b>Speaker:</b> Ming Sun, Shenzhen Rui Therapeutics Co., Ltd., CSO 13:00-14:00   Panel discussion: Expansion of Cell Therapy Indications and Clinical Development Strategies <b>Panelists:</b> Lun Zeng, MBA, XLifeSc, CEO Tongcun Zhang, Bio-Raid Biotechnology, Founder Liqun Wang, Neukio Biotherapeutics, CEO Zhao Wu, Innovative Cellular Therapeutics, Co-Founder &amp; President Zhinan Yin, Jide Kongming Biomedical, Professor &amp; Dean, Founder &amp; Chairman</p>	<p><b>Indication Development &amp; Clinical Breakthroughs – Rare Diseases</b> 12:00-12:20   Presentation: Clinical Progress and Accessibility Breakthroughs of AAV Gene Therapy for Retinal Diseases <b>Speaker:</b> Amy Chen, Chengdu Genevector Biotechnology Co., Ltd., VP 12:20-13:00   Panel discussion: Gene Therapy Development Strategies for Rare Diseases <b>Panelists:</b> Dr. Yixiong Chen, Shanghai Lingyi Biotech Co., Ltd., CSO Amy Chen, Chengdu Genevector Biotechnology Co., Ltd., VP Xiaoyan Dong, GeneCradle, Co-Founder Guixi Zhang, Gritgen Therapeutics, CTO</p> <p><b>Indication Development &amp; Clinical Breakthroughs – Ophthalmology</b> 13:00-13:20   Presentation: Innovative AAV Vectors Targeting Heart/Muscle and Development of Long-Acting Heart Failure Gene Therapy <b>Speaker:</b> Lei Zhao, Cure Genetics Co., Ltd., Executive Director 13:20-14:00   Panel discussion: Gene Therapy Development Strategies for Ophthalmic Diseases <b>Panelists:</b> Dr. Kai Wu, UgeneX Therapeutics President Zhenhua Wu, Exegenesis Bio Inc., Founder &amp; CEO Sikai Ling, Bendaqin Gene, VP of R&amp;D</p> <p><b>Indication Development &amp; Clinical Breakthroughs – Chronic Diseases</b> 14:00-14:20   Presentation: Applications of Innovative Base Editing Technologies in Metabolic Diseases <b>Speaker:</b> Susan Mou, CorrectSequence Therapeutics, CEO 14:20-15:00   Gene Therapy Development Strategies for Chronic Diseases <b>Panelists:</b> Yang Hu, Lumiere Therapeutics (Suzhou)Co., LTD, CEO Robin Tan, Refreshgene Therapeutics, Co-Founder &amp; CTO Susan Mou, Ph.D., CorrectSequence Therapeutics, CEO Qing Lin, Lingyi Biotech, CEO</p>
14:00-15:00	Networking & Events	Networking & Events	<p><b>CMC and Regulatory Submission</b> 15:20-15:40   Coordinated Development of Biomedical Technologies and Drug Submission <b>Speaker:</b> Ping Li, Exegenesis Bio, Senior Director, Regulatory</p> <p>15:40-16:20   Panel discussion: IIT/Clinical Perspectives on CMC Development Requirements <b>Panelists:</b> Herman He, SineuGene Therapeutics Co., Ltd., CMC Head Xikui Gong, Fosun Pharma, Director, CMC Jun Xiao, Shanghai Vitalgen BioPharma, Quality VP Hongxing Wang, Euhearing Therapeutics, CTO Xudong Zhu, Kanglin Biotech, Quality Director</p>
15:00-18:00	<p><b>Executive Panel Discussion</b> 15:00-15:40   Panel discussion: Innovative Breakthroughs in Exosome Development <b>Panelists:</b> Haoran Wang, Newland Biotechnology, CEO Xiaohu Ge, Tianjin Exosome Technology Co., Ltd., Chairman Dr. Grace Zhou, ImmVira Pharma, CEO Guanyi Kong, Echo Biotech, CEO</p> <p><b>Exosome Delivery and Carrier Research</b> 15:40-16:00   Presentation: Engineering Exosomes on the OVPENS Platform: Innovative R&amp;D and Applications <b>Speaker:</b> Xiaoqing Chen, ImmVira Bioscience, CSO 16:00-16:20   Presentation: Engineered Exosomes Crossing the Blood-Brain Barrier: A New Paradigm for CNS Nucleic Acid Drug Delivery <b>Speaker:</b> Tinghe Wu, Cohen-Ris Biopharm, Founder &amp; CEO 16:20-16:40   Presentation: Smart Targeted Drug Delivery Platform</p> <p><b>Exosome Clinical Translation Research</b> 16:40-17:00   Presentation: Tumor Combination Therapy 17:00-17:20   Presentation: Neurodegenerative Diseases</p> <p><b>Exosome Large-Scale Production Process Optimization</b> 17:20-17:40   Presentation: Separation and Purification 17:40-18:00   Presentation: Large-Scale Production Optimization Strategies</p>	<p><b>Solid Tumor Drug Development</b> 15:00-15:20   Presentation: Development of the World's First Autologous CAR-T Therapy <b>Speaker:</b> ZongHai Li, CARgen, Founder &amp; CEO 15:20-15:40   Presentation: gdT Cells: A New Frontier in Solid Tumor Cell Therapy <b>Speaker:</b> Zhenan Yin, Jide Kongming Biomedical, Professor &amp; Dean, Founder &amp; Chairman 15:40-16:00   Presentation: Clinical Progress of CoupledCAR Platform Technology for Advanced Solid Tumors <b>Speaker:</b> Zhao Wu, Innovative Cellular Therapeutics, Co-Founder &amp; President 16:00-16:20   Presentation: Advances in Cell Therapy for Hepatocellular Carcinoma <b>Speaker:</b> XiaoWu Huang, Zhongshan Hospital, Fudan University, Director of the Biotherapy Center, Professor and Chief Physician of Hepatobiliary Oncology and Liver Transplantation 16:20-16:40   Presentation: Ultra-Low Dose Metabolism-Enhanced Cell Therapy <b>Speaker:</b> Dudu Tong, Leman Biotech, Executive Director 16:40-17:00   Presentation: TCR-T Development for Solid Tumors <b>Speaker:</b> Kai Zhang, XLifeSc, General Manager Assistant, BD Director &amp; Senior Scientist 17:00-17:20   Presentation: CAR-NK Development for Solid Tumors <b>Speaker:</b> Xiangfeng He, Inber Biotech, CEO 17:20-17:40   Presentation: Exploring Curative Strategies for Solid Tumors <b>Speaker:</b> Meijia Yang, Ph.D., NaviGen Bio, Founder and Chairman 17:40-18:00   Presentation: TBC <b>Speaker:</b> Tianhong Xu, Base Therapeutics, Founder &amp; CEO</p>	<p><b>Back to Contents</b></p>

# BIOCHINA2026 Biomanufacturing Innovative Development Forum

Date	March 12th	March 13th	March 14th
09:00-11:00	Exhibition Hall Closed During Opening Ceremony	<b>Agricultural Innovation</b> 09:00-09:20   Presentation: Straw-Based Biomanufacturing to Drive Agricultural Innovation <b>Speaker:</b> Cheng Li, PolyView Biotechnology, Co-Founder & CTO 09:20-09:40   Presentation: Breaking the Production Bottleneck in Cell Factories: Bacillus Lipopeptides Revitalizing Industries and Nature <b>Speaker:</b> Yukang Xie, Ph.D., SYN Biotechnology, Co-Chief Scientist 09:40-10:00   Presentation: Intelligent Production and Industrialization of Microbial Proteins from Straw-Based Feedstocks <b>Speaker:</b> Zhenyun Liu, Yixi Biotech, Founder & CEO 10:00-10:20   Presentation: Bio-Substitute of White Mustard Alkaloid: From Plant Extraction to Yeast-Based Synthesis <b>Speaker:</b> Yan Feng, Shanghai Jiao Tong University, Distinguished Professor & Deputy Director, State Key Laboratory of Microbial Metabolism 10:20-11:00   Panel Discussion: Agricultural Innovation through Biomanufacturing <b>Panelists:</b> Cheng Li, PolyView Biotechnology, Co-Founder & CTO Yukang Xie, Ph.D., SYN Biotechnology, Co-Chief Scientist	<b>AI + Biomanufacturing</b> 09:00-10:00   Panel Discussion: The Future Transformation of AI + Biomanufacturing 10:00-10:20   Presentation: Construction of High-Expression Strains Using AI <b>Speaker:</b> Yongliang Zhu, Pryson Technology, Chairman & CSO 10:20-10:40   Presentation: TBC <b>Speaker:</b> Zishuo Zeng, Synceres Biosciences, R&D Director & Bioinformatics Scientist 10:40-11:00   Presentation: Intelligent Control of Bioreactor Processes
	10:00-10:30   Presentation: Biomanufacturing Driving a Revolution in Pharmaceutical Development 10:30-11:00   Presentation: Chassis-Free In Vitro Biotransformation (ivBT) Enabling Dimensionality-Reduced Biomanufacturing <b>Speaker:</b> Yiheng Zhang, Tianjin Institute of Industrial Biotechnology, CAS, Director, Center for In Vitro Synthetic Biology & National Key Lab of Low-Carbon Synthetic Biology		
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<b>Food Development</b> 12:00-12:20   Presentation: Compliance and Standardization of New Food Ingredients from Synthetic Biology <b>Speaker:</b> Ming Liu, China National Research Institute of Food & Fermentation Industries, Deputy Director, Standards & Digitalization R&D Department 12:20-12:40   Presentation: Creation and Applications of Next-Generation Microbial Proteins <b>Speaker:</b> Xianzhi Jiang, MoonBiotech, Founder & CEO 12:40-13:00   Presentation: Development of Bio-Cell Factory for Food-Medicine Homology High-Activity Compounds (AKG, Ganoderic Acids, Ganoderma Polysaccharides, etc.) <b>Speaker:</b> Yifa Yu, Nanning Harworld Biological Technology, Executive Vice General Manager & Director, R&D 13:00-13:20   Presentation: Research and Development of ZhiYi Bio's Next-Generation Probiotic AKK-AM06 <b>Speaker:</b> Yangyang Liu, Zhiyi Biotechnology, Deputy General Manager & Co-Founder 13:20-13:40   Presentation: Smart Engineering of Animal Cells for Cultivated Meat Applications <b>Speaker:</b> Andy Tan, Bioprocessing Technology Institute, A*STAR, Principal Scientist and Group Leader 13:40-14:00   Presentation: Safety Evaluation Technologies for Genetically Modified Microorganisms and Their Application in Novel Food Approval <b>Speaker:</b> Lei Zhai, China National Research Institute of Food & Fermentation Industries, Director, Biotechnology R&D Department	<b>Agricultural Innovation</b> 12:00-14:00   Agriculture Innovation Session 12:00-12:20   Presentation: Enhancing Agricultural Productivity through the Microbiome 12:20-12:40   Presentation: Development of Novel Biofertilizers and Animal Feed 12:40-13:00   Presentation: Cultivation of Functional Crops 13:00-13:20   Presentation: Development of Biopesticides and Formulations 13:20-14:00   Panel Discussion: Empowering Agricultural Innovation with Synthetic Biology	<b>AI + Biomanufacturing</b> 12:00-12:20   Presentation: AI-Designed Metabolic Pathways for Greener Cosmetic Ingredients 12:20-12:40   Presentation: AI-Assisted Recombinant Collagen Molecular Design 12:40-13:00   Presentation: AI-Driven Design of Biocatalytic Enzymes <b>Enzyme &amp; Metabolic Engineering</b> 13:00-13:20   Presentation: NMR-Guided Directed Evolution of Enzymes <b>Speaker:</b> Lichun He, Ph.D., Chinese Academy of Sciences (CAS), Professor 13:20-13:40   Presentation: Biosynthesis of Non-Natural Compounds Driven by Enzyme Engineering <b>Speaker:</b> Lipo Zhang, Westlake University, Distinguished Researcher 13:40-14:00   Presentation: Spatial Capability Design of Enzymes and Biosynthesis <b>Speaker:</b> Zhoutong Sun, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Researcher <b>Cell Factories &amp; Industrial Strain Industrialization</b> 14:00-14:20   Presentation: Construction of Efficient Microbial Cell Factories Based on Synthetic Biology and Their Industrial Applications <b>Speaker:</b> Zhiming Rao, Jiangnan University, Associate Dean, School of Biochemical Engineering
	<b>Networking &amp; Events</b>	<b>Networking &amp; Events</b>	14:20-14:40   Presentation: Halomonas Chassis Design and Its Applications in Biomanufacturing <b>Speaker:</b> Jianwen Ye, South China University of Technology, Professor, School of Biological Science and Engineering 14:40-15:00   Presentation: Reprogramming and Optimization of High-Yield Industrial Strains for Stable Production and Industrial Applications <b>Speaker:</b> Shihui Yang, Wuhan Ruijiakang Biotech, Professor, Hubei University & Founder, Wuhan Ruijiakang Biotech 15:00-16:00   Panel Discussion: Accelerating Biomanufacturing Industry Development through Research <b>Panelist:</b> Shihui Yang, Wuhan Ruijiakang Biotech, Professor, Hubei University & Founder, Wuhan Ruijiakang Biotech
14:00-15:00	<b>Food Development</b> 15:00-15:20   Presentation: TBC <b>Speaker:</b> Jingya Zhao, Zeno Technology, Deputy General Manager & COO 15:20-15:40   Presentation: Production Strategies from Non-Food Biomass to Microbial Proteins <b>Speaker:</b> Fengli Zhang, Shanghai Jiao Tong University, Associate Researcher, School of Life Science and Technology 15:40-16:30   Panel Discussion: Opportunities in Biomanufactured Food from Different Perspectives <b>Panelist:</b> Ying Zhang, SDIC Convergence Investment Management Co., Ltd., Investment Director Yifa Yu, Harworld Biotech, EVP & R&D Director	<b>Aesthetic Biotechnology</b> 15:00-18:00   Cosmeceuticals and Biomanufacturing Session 15:20-15:40   Presentation: TBC <b>Speaker:</b> Ruiyan Wang, Huaxi Biotech, General Manager, Raw Material R&D Center 15:40-16:00   Presentation: New Cosmetic Ingredients – Single-Cell Microalgae Extracellular Vesicles <b>Speaker:</b> Yujiao Qu, Protaga Biotech, Chief Biotechnology Officer & Deputy Director, Microalgal Biosynthesis R&D Center, Tsinghua Shenzhen International Graduate School 16:00-16:20   Presentation: TBC <b>Speaker:</b> Wenge Wang, 江大生物, Chairman & CEO 16:20-16:40   Presentation: TBC <b>Speaker:</b> Zhiqian Yan, 深圳微智生物, CEO 16:40-17:00   Presentation: Application of Biosynthetic Regenerative Microspheres in Cosmeceuticals 17:00-17:20   Presentation: Development of Long-Chain Recombinant Collagen Products 17:20-18:00   Panel Discussion: Process Innovation and Product Development <b>Panelist:</b> R.X. Lee, HighLight Capital, Director	
15:00-18:00	<b>Fermentation Track</b> 16:30-16:50   Presentation: Customized Construction of Novel Fermentation Platforms and Industrialization Enablement 16:50-17:10   Presentation: Scale-Up Technologies and Industrialization Case Studies of 10,000-Ton Industrial Fermenters 17:10-18:00   Panel Discussion: Collaborative Pathways for Novel Fermentation Platforms Across Academia, Industry, and Capital — Technology Licensing, Production Line Implementation, and Multi-Party Win-Win <b>Panelist:</b> Lei Zhai, China National Research Institute of Food & Fermentation Industries, Director, Biotechnology R&D Department		

Back to Contents

# BIOCHINA 2026 Roadshow

Date	March 12th	March 13th	March 14th
9:00-11:00		<p><b>In Vivo CAR-T Roadshow</b>  <b>Special Guests:</b> Ning Li, Gaorong Ventures, ED  Karen Liu, Ph.D., 3E Bioventures Capital,  Founding Partner  Xiaoxiao Peng, InnoPinnacle Fund, Managing  Director  Project: In Vivo CAR-T Based on Antibody Non-Chemical Site-Specific Conjugated LNP Technology  Funding Stage: Angel</p>	<p><b>Artificial Intelligence Roadshow</b>  <b>Special Guests:</b> Yuqin Zhang, Proxima Capital, Vice Director</p> <p><b>Scientific Research Roadshow</b>  <b>Special Guests:</b> Liqiong Pang, CASVC, ED</p> <ol style="list-style-type: none"> <li>Small-Molecule Drug Conjugate (SMDC) Delivery / Oral Platform and Innovative Drug Development</li> <li>Original Dual-Pathway Innovative Drug Development for Coronary Heart Disease</li> <li>Cytokine Prodrug Development for Cancer Immunotherapy</li> <li>Dual-Mechanism PCC Molecules Against Deep-Seated Fungal Infections</li> </ol>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>Innovative Drug Roadshow</b>  <b>Special Guests:</b> Dr. Vince Deng, Med-Fine Capital, Partner  Daniel Ying, Orbimed, Executive Director  Tingzhi Qian, Prosperico Ventures, Funding Partner  Hua Yi, SDIC Capital, Director &amp; General Manager</p> <ol style="list-style-type: none"> <li>Project: Nanobody ADC Targeting GPC3 (NDC)  Funding Stage: Angel + Pre-A</li> <li>Project: Innovative Organ-Targeted Oligonucleotide Therapeutics  Funding Stage: Angel</li> <li>Project: FIC Small-Molecule Autophagy and Apoptosis Inducers for Alzheimer's Disease, Chronic Cancer Pain, and Gastric Cancer  Funding Stage: Angel</li> <li>Project: Discovery and Clinical Development of <math>\alpha</math>-Radionuclide <math>^{211}\text{At}</math>-Labeled Targeted Radiopharmaceuticals for Cancer Therapy  Funding Stage: Series A</li> <li>Project: Gene Therapy for Heart Failure  Funding Stage: Pre-A</li> <li>Project: Global Innovative Small-Molecule Immuno-Oncology Agonists  Funding Stage: Pre-A</li> <li>Project: Novel Bispecific ADC Molecule for Glioma Treatment  Funding Stage: Pre-A</li> <li>Project: "Lightning Pathway" Program — Rapid Engine for CGT Commercialization in the First Golden Year Following the Implementation of Regulation 818  Funding Stage: Angel</li> </ol>	<b>BD Partnership Roadshow</b>	<p><b>Biomanufacturing Roadshow</b>  <b>Special Guests</b></p> <ol style="list-style-type: none"> <li>Project: Non-Animal-Derived Single-Cell Recombinant Exosome Technology and Its Intelligent Manufacturing &amp; Industrialization Platform  Funding Stage: A+</li> </ol>
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	<p><b>Innovative Technologies &amp; Therapies Roadshow</b>  <b>Special Guests</b></p> <ol style="list-style-type: none"> <li>Project: Sub-Centimeter Liver Cancer (<math>\leq 10</math> mm) MRI Early Screening Technology (Nayouming®)  Funding Stage: Angel</li> </ol>	<p><b>15:00-16:30   Korea-Focused Projects Roadshow</b>  <b>Special Guests:</b> Marc Appel, Pacific Bridge, Managing Partner  Hugh Xu Huang, Pfizer, Discovery Network-Director &amp; External Science Lead China</p>	<p><b>Back to Contents</b></p> <p><b>27</b></p>

## BIOCHINA 2026 Brainstorming

Date	March 12th	March 13th	March 14th
9:00-11:00	Exhibition Hall Closed During Opening Ceremony	<p><b>Cell Therapy R&amp;D</b> 09:00-10:00   Opportunities and Key R&amp;D Points for CGT Therapies under Regulation 818 <b>Speaker:</b> Yansheng Dong, SAFE Pharmaceutical, SVP</p> <p><b>Practical Key Points in Clinical Research Data Management and Audit</b> 10:00-11:00   Presentation: Internationalization of Clinical Development — Case Studies in Autoimmune and Metabolic Diseases <b>Speakers:</b> Heng Su, ICON, Head of Business, Greater China Wanni Zhao, ICON, Director of Business, Central Laboratory</p>	<p><b>Cell Therapy CMC and Regulatory Focus</b> 09:00-10:00   Panel Discussion: Challenges in Differentiated Process Development for Autologous and Allogeneic Cell Therapies</p> <ul style="list-style-type: none"> <li>Key Differences in Process Design and Development</li> <li>Commercialization and Cost Considerations</li> </ul> <p><b>Panelist:</b> Fenghua Lv, Base Therapeutics (Shanghai) Co, Ltd., Senior Director of CMC and Head of Quality 10:00-10:45   Presentation: Low-Cost Process Solutions for Cell Therapy <b>Speaker:</b> Yanzhou Huang, SCG, Vice President of Process Development</p> <ul style="list-style-type: none"> <li>Changes in the Technical Framework</li> <li>Replacement and Upgrade of Existing Solutions</li> </ul> <p>10:45-11:00   Q&amp;A</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>Peptide Session</b> 12:00-13:00   Cyclic Peptide Development</p> <ul style="list-style-type: none"> <li>Molecular Design, Screening, Synthesis, Safety</li> <li>Application Potential: Pharmaceutical, Cosmetic</li> </ul> <p>13:00-13:30   Presentation: Advancing Precision Oncology with Next-Generation Peptide Cancer Vaccines <b>Speaker:</b> Asma Khanniche, Andra Biology, R&amp;D director</p> <p>13:30-14:00   Presentation: GLP-1 Multi-Target Approaches and New Indication Expansion <b>Speaker:</b> Li Zhang, Pyrovita Therapeutics, CTO</p>	<p><b>Conjugated Drugs Focus</b> 12:00-13:00   PDC Conjugates 13:00-14:00   AOC: Antibody-Oligonucleotide Conjugates <b>Speaker:</b> Yanming Shen, Porton Pharma Solutions Ltd., Director of R&amp;D, Biologics Drug Development &amp; Manufacturing Center</p>	<p><b>Cell Therapy Quality Session</b> 12:00-13:00   Panel Discussion: Challenges and Innovative Practices in Cell Therapy Quality Control</p> <ul style="list-style-type: none"> <li>Release Testing for Live Cell Products</li> <li>Residuals in Viral Vector Processes</li> <li>Potency Assay Methods</li> </ul> <p><b>Panelists:</b> Mingyang Gu, Nanjing AcroImmune Biopharmaceutical Co. Ltd, General Manager Assistant Meiling Wang, PRECISION BIOTECH, QC Lead Rui Li, Neukio Biotherapeutics, Senior Director of Quality 13:00-14:00   Panel Discussion: Global Regulatory Approval and Lifecycle Management of Cell Therapy Products</p> <ul style="list-style-type: none"> <li>Strategies and Post-Market Changes Across Different Regulatory Systems (China, US, EU)</li> <li>Indication Expansion and Real-World Data Applications</li> </ul> <p><b>Panelists:</b> Shuping Fang, Simcere, Director Yingyi Shu, Shanghai Protocell Medical Technology Co., Ltd., Senior Registration Director</p>
14:00-15:00	Networking & Events	Networking & Events	<p><b>Stem Cell Session</b> 14:00-15:00   Indication Expansion of Stem Cell Therapies: From Rare Diseases to Common Diseases</p>
15:00-18:00	<p><b>Antibody Session</b> 15:00-16:00   Panel Discussion: Quality Analysis and Quality Management</p> <ul style="list-style-type: none"> <li>Accelerating Development of Biologics Quality Attribute Analytical Methods Using New Technologies</li> <li>Case Studies on Quality Management</li> </ul> <p><b>Panelists:</b> Qingmin Wang, Qilu Pharmaceutical, Executive Director, Biotech Development Institute DaiDi Hu, CSPC Megalith Biopharmaceutical, Head of Quality Department 16:00-17:00   Presentation: Insights from Onsite Inspections of Overseas Manufacturing of Imported Drugs <b>Speaker:</b> Terry Lu, Harbour BioMed, Quality Director</p>	<p><b>Conjugated Drugs Focus</b> 15:00-15:30   Presentation: ADC Process Development: Key CMC Pathways from Clinical to Commercialization <b>Speaker:</b> Zhiping Yao, Haoyuan Chemexpress, CTO 15:30-16:00   Presentation: Key Considerations in Small-Molecule ADC CMC <b>Speaker:</b> Xianglin Zhao, Haoyuan Chemexpress, Deputy General Manager, Innovative Drug Services Division 16:00-17:00   RDC-Radionuclide Conjugated Drugs 17:00-18:00   Commercial-Scale ADC Manufacturing</p> <ul style="list-style-type: none"> <li>ADC Workshop Protection (Use of Disposable Clean Suits and PPE)</li> <li>Small-Molecule Inactivation (Inactivation of Small-Molecule Toxins in ADC Production)</li> <li>Waste Management (Full-Process Classification and Compliance)</li> <li>ADC Toxin Handling (Risk Control Throughout Production Process)</li> </ul>	

# BIOCHINA 2026 Brainstorming

Date	March 12th	March 13th	March 14th
9:00-11:00		<p><b>Radiopharmaceuticals Session</b> 09:00-09:45   Presentation: Overview of Radiopharmaceutical Regulations in China <b>Speaker:</b> Shaofeng Zhang, BoomRay Pharmaceutical Co., Ltd., QA Assistant Director 09:45-10:00   Q&amp;A Session 10:00-11:00   Quark Pharma Special Focus Panel Discussion: Innovative Translational Pathways and Global Industrial Strategy in Radiopharmaceutical Development</p> <ul style="list-style-type: none"> <li>• Breaking Traditional Target Limitations: Development Pathways and Clinical Application of Emerging Targets</li> <li>• Going Global: Market, Collaboration, and Supply Chain Challenges in Radiopharmaceuticals</li> </ul>	<p><b>Antibody R&amp;D Session</b> Innovative Approaches in Bispecific Antibody Molecular Design 09:00-09:20   Presentation: Development Progress and Considerations of Brain-Penetrant Antibodies <b>Speaker:</b> Dong Yang, 4B Technologies Investments, Director of R&amp;D</p> <p><b>Autoimmune Diseases Session</b> 10:00-10:20   Presentation: Autoimmune-Related Research</p>
11:00-12:00	Lunch & Networking	Lunch & Networking	Lunch & Networking
12:00-14:00	<p><b>In Vivo CAR-T Session</b> 12:00-13:00 Presentation: From Characterization to Scale-Up: Key Parameters and Quality Control of In Vivo CAR-T Manufacturing <b>Speaker:</b> Xin Wu, Levostar Life Sciences, Founder &amp; CEO 13:00-14:00 Interview, In Vivo CAR Companion Diagnostics <b>Moderator:</b> Jianfei Zhang, Kaijie Conversion Medical, BD Director</p> <p>13:00-13:05 Opening 13:05-13:30 Presentation: TBC <b>Speaker:</b> Fengtao You, PersonGen BioTherapeutics, Director Innovative Drug Research Institute 13:30-13:55 Presentation: TBC <b>Speaker:</b> Zhengguo Pang, Kaijie Conversion Medical, Senior Director 13:55-14:00 Q&amp;A</p>	<p><b>Artificial Intelligence Session</b> 12:00-13:00   Panel Discussion: Accelerating Early-Stage Scientific Discovery with AI – Case Studies <b>Moderator:</b> Yaxian Zhao, PhD in Neurophysiology, Host of the technology podcasts <b>Panelist:</b> Jue Wang, InSilico Medicine Cayman TopCo, VP of Business</p> <p>13:00-14:00   Case Studies in AI and Engineering Automation</p>	<p><b>Small Molecule Innovation &amp; Development Session</b> 12:00-13:00   Clinical Translation Strategies 13:00-14:00   CMC and Manufacturing 14:00-15:00   PPQ: Process Performance Qualification</p>
14:00-15:00	Networking & Events	Networking & Events	
15:00-18:00	<p><b>Immuno-Cell Therapy Session</b> 15:00-16:00   Gene-Edited TIL Product Development <b>Speaker:</b> Dr. Aotian Xu, Huasaiboman Medical Cell Biology Co., Ltd., Senior R&amp;D Director</p> <p><b>Cold Chain Logistics Session</b> 16:00-17:00   Cold Chain Transportation for Biologics <b>Speaker:</b> Jianming He, Yingji Pharmaceutical, Regional Marketing Director</p> <p><b>Cell Therapy Manufacturing and Quality Control Session</b> 17:00-18:00   Panel Discussion: From “Workshop” to “Smart Factory”: Scaling Up Cell Therapy Manufacturing</p> <ul style="list-style-type: none"> <li>• Automation, Cost Reduction &amp; Efficiency, and Product Quality Consistency</li> </ul> <p><b>Panelists:</b> Liang Su, BRL Medicine, Manufacturing Director Shouliang Wu, Vcanbio Cell &amp; Gene Engineering Corp., Ltd., Manager of Manufacturing Science &amp; Technology Yusheng Qu, XLifeSc, Director of Cell Preparation</p>	<p><b>Organoids for Drug Development Tumor Organoids Session</b> 15:00-15:20   Presentation: TBC 16:00-17:00   Organoids for Neurodegenerative Diseases 17:00-18:00   Organoids for Metabolic Diseases</p>	

# BIOCHINA 2026 (11th Edition) Agenda

Time	Close-door Meeting	Main Stage 1	Main Stage 2	BIOCHINA Reception	BIOCHINA Activities
Mar12	09:00-10:00	/	BIOCHINA Awards: Annual Supplier Ceremony	/	
	10:00-11:00		BIOCHINA International Dialogue <b>Moderator:</b> Maxwell Kirkby, Huang and Kirkby Medical Consulting, CEO		
	11:00-12:00	Networking	Mr. Alexandre Cérat, Consulate General of Canada in Shanghai, Deputy Consul General & Commercial Officer Sjord Dikkerboom, Netherlands Innovation Network, Officer for Innovation, Technology & Science	BIOCHINA Bio Festival Runway Show <b>New Product Launches</b> ProBio Technology Sunresin Duoning Biotech Pan Dai, 百思飞, Executive Director & General Manager	Procurement Lunch Meeting
	12:00-13:00	Government & Regulatory Close-door Meeting	/	/	
	13:00-14:00		BIOCHINA Bio Festival Life Stories Lecture Hall Aimin Hui, EnCureGen Pharma, Founder, Chair & CEO Yong Tao, Beijing Chaoyang Hospital, Capital Medical University, Dept. Ophthalmology	BIOCHINA International Supply & Procurement Dialogue <b>Vladimir Popov, ROSBIOTECH &amp; ESMAR Ltd., Professor &amp; CEO</b>	Open
	15:00-16:00	Biomanufacturing Close-door Meeting	/	/	
	16:00-17:00	Emerging Regions International Exchange Closed-Door Session			
	17:00-18:00				
	18:00-20:00				BIONIGHT Invitational Dinner
	09:00-10:00	Upstream International Expansion Close-door Meeting	/	/	
Mar13	10:00-11:00				
	11:00-12:00	Networking	BIOCHINA CEO Dialogue Panel Discussion: Our Drug Launch Journey in 2025 Ziye Sui, Lepu Biopharma Co., Ltd., CEO Yanjun Xu, Xuanzhu Biotech, Chairman Cheng Qian, Precision Biotech, Chairman & CSO	BIOCHINA Bio Festival Awards <b>New Product Launches</b> Incess: Eight-Channel Purification, Fast & Smart — Launch of the Inscinstech 8-Channel Fully Automated Protein Purification System Tao Zhang, Incess, Chromatography Product Manager Challenge IM Guiling Jia, Challenge IM, Founder & CEO	ExCell Bio Lunch Meeting
	12:00-13:00	PI Face-to-Face – Metabolism	/	/	
	13:00-14:00	International Regulatory Closed-Door Meeting – Indonesia			
	14:00-15:00	Networking	BIOCHINA Upstream Dialogue Panel Discussion: Rebuilding Symbiosis: The "Partner" Era of International Innovation Ecosystems <b>Moderator:</b> Li Jia, Lang Sheng Investment, Partner Yan Gu, Crown Bioscience, CEO Dr. Jijie Gu, WuXi Biologics, CSO & President of Global Biologics Research Christian Schmidtgen, Bayer Pharmaceuticals, Head of R&D Finance, Resource & CRO Management	BIOCHINA CSO Dialogue Panel Discussion: A Scientist Who Doesn't Do BD Isn't a Good CSO – Maximizing Pipeline Value Through Endless Innovation Iterations <b>Moderator:</b> Yaxian Zhao, PhD in Neurophysiology, Host of the technology podcasts Dr. Yiping Rong, Harbour BioMed, CSO Jiaqiang Cai, Ph.D., MediLink Therapeutics, Co-Founder, Co-CEO & CSO	Sino-Dutch Life Sciences Delegation · Networking Reception
Mar14	15:00-16:00	International Regulatory Meeting – Pakistan	/		
	16:00-17:00	PI Face-to-Face – Metabolism			
	17:00-18:00	PI Face-to-Face – CNS			
	18:00-20:00	Networking			Korea Night CSO & CMO Reception CTO Reception
	09:00-10:00	/	/	/	
Mar14	10:00-11:00				
	11:00-12:00	Research Translation Close-door Meeting	BIOCHINA 2026 Annual Product Awards Ceremony BIOCHINA CTO Dialogue <b>Moderator:</b> Junhua Qiao, GeneScience Pharmaceutical, CTO	BIOCHINA CMO Dialogue	Open
	12:00-13:00				
	13:00-14:00				
	14:00-15:00				

[Back to Contents](#)

# Join us at BIOCHINA2026



►► BIOCHINA ◀◀◀

Connecting Innovators, Enabling Bio-industry.  
China's leading communication platform in Bio-industry



►► BioBD Group ◀◀◀



►► BIOCHINA GCD Group ◀◀◀  
(Global Clinical Group)



►► WhatsApp Group ◀◀◀